var title_f13_57_14224="AC joint compression test - Part 1";
var content_f13_57_14224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AC joint compression test: Part 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain elicited by compression of the acromioclavicular (AC) joint suggests an AC disorder. Testing is performed in two parts. Positioning for part one is pictured above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14224=[""].join("\n");
var outline_f13_57_14224=null;
var title_f13_57_14225="Pneumonia prevention";
var content_f13_57_14225=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pneumonia prevention (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/57/14225/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14225/contributors\" id=\"au364\">",
"       Patricia L Hibberd, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/57/14225/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14225/contributors\" id=\"se136\">",
"       John G Bartlett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/57/14225/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14225/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/57/14225?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The most common cause of pneumonia in the United States is the bacterium Streptococcus pneumoniae, or pneumococcus. The pneumococcal vaccine is the best way to prevent infection with pneumococcus. The influenza vaccine can also help to prevent pneumonia, which can develop as a complication of the flu. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This topic discusses the pneumococcal vaccine, including who should be vaccinated and the potential benefit of vaccination. Symptoms and treatment of pneumonia are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"      \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PNEUMONIA VACCINE",
"     </span>",
"    </p>",
"    <p>",
"     The pneumococcal vaccine protects against the most common types of pneumococcal bacteria. Protection against pneumococcus has become more important as difficult to treat strains of pneumococcus have emerged.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Types of vaccine",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two types of pneumococcal vaccine available in the United States,",
"     <strong>",
"      PPSV23",
"     </strong>",
"     (pneumococcal polysaccharide vaccine 23) and",
"     <strong>",
"      PCV13",
"     </strong>",
"     (pneumococcal conjugate vaccine13).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       PCV13 is recommended for children. Four doses are given at age 2, 4, 6, and 12 to 15 months. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"        \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       PPSV23 is recommended for everyone older than 65 years old, as well as for anyone over age 2 years who is at high-risk for pneumonia.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Who needs vaccination?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Current guidelines recommend giving one dose of the pneumococcal vaccine to everyone aged 65 years or older if they have not previously been vaccinated. For people who were given the vaccine before age 65, a one-time revaccination is recommended after 5 years. Patients with a weakened immune system should also be revaccinated one time 5 years or more after the first dose of vaccine.",
"    </p>",
"    <p>",
"     Younger people who are at risk of pneumococcal disease includes people with diabetes mellitus, heart and lung disease, alcoholism, liver disease, cerebrospinal fluid leaks, cochlear implants, those with a weakened immune system, those who have no spleen, adults who smoke cigarettes, and people living in special environments (eg, nursing home residents).",
"    </p>",
"    <p>",
"     Those aged 2 to 64 years who are at risk for pneumonia should be given the vaccine when the need for immunization is recognized. Women who are pregnant or who intend to become pregnant should receive the vaccine if they have an indication.",
"    </p>",
"    <p>",
"     Anyone who develops pneumococcal pneumonia who has not been vaccinated previously should be vaccinated; infection with one strain of the bacteria does not necessarily protect the person against infection with other strains.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Need for booster vaccination",
"     </span>",
"     &nbsp;&mdash;&nbsp;The need for a one-time booster vaccine depends up an individual's circumstances. As discussed above, for people who were given the vaccine before age 65, a one-time revaccination is recommended after 5 years. Patients with a weakened immune system should also be revaccinated one time 5 years or more after the first dose of vaccine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Other vaccines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Influenza vaccine (the flu shot) is also recommended for all people who are at least 6 months of age, but is especially important for those who are at high-risk for pneumonia since pneumonia is a common complication of influenza infection. It is given once per year, usually between October and January in the United States. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      \"Patient information: Influenza prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pneumococcal vaccine cannot prevent all cases of pneumonia. Thus, anyone who is at high-risk for either pneumonia or influenza should discuss the benefits of vaccination with their healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      INFECTION CONTROL",
"     </span>",
"    </p>",
"    <p>",
"     Infection control measures can help to prevent the spread of any type of infection, including pneumonia. Infection control is most commonly practiced in healthcare settings, but is useful in the community as well. Frequent hand washing with soap and water or alcohol-based hand rubs can be effective.",
"    </p>",
"    <p>",
"     Because pneumonia is spread by contact with infected respiratory secretions, people with pneumonia should limit face-to-face contact with uninfected family and friends. The mouth and nose should be covered while coughing or sneezing, and tissues should be disposed of immediately.",
"     <span class=\"nowrap\">",
"      Sneezing/coughing",
"     </span>",
"     into the sleeve of one's clothing (at the inner elbow) is another means of containing sprays of saliva and secretions and has the advantage of not contaminating the hands.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498629980\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15696821\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/29/12754?source=see_link\">",
"      Patient information: Community-acquired pneumonia in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/48/15107?source=see_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/24/7554?source=see_link\">",
"      Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/19/8498?source=see_link\">",
"      Patient information: Chronic granulomatous disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/44/14019?source=see_link\">",
"      Patient information: Mycoplasma pneumonia in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15696828\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"      Immunizations during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000145.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000145.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     , click on \"Diseases A to Z\", then click on \"P\")",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Canadian Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.lung.ca/pneumonia\">",
"      www.lung.ca/pneumonia",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/57/14225/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/57/14225?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14225/abstract/1\">",
"      Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14225/abstract/2\">",
"      Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14225/abstract/3\">",
"      Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; :CD000422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_57_14225=[""].join("\n");
var outline_f13_57_14225=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PNEUMONIA VACCINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           INFECTION CONTROL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14226="SC central line supra";
var content_f13_57_14226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Supraclavicular approach to the subclavian vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The supraclavicular approach allows ready access to the subclavian vein. The point of needle entry lies 1 cm posterior to the sternocleidomastoid and 1 cm superior to the clavicle. Be sure the angle of the needle is depressed 10 to 15 degrees below the coronal plane (ie, needle tip aimed upwards). Advance the needle behind the medial clavicle along a trajectory directed just below the contralateral nipple.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14226=[""].join("\n");
var outline_f13_57_14226=null;
var title_f13_57_14227="Treatment of precancerous cells of the cervix";
var content_f13_57_14227=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/57/14227/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14227/contributors\" id=\"au5145\">",
"       William J Mann, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/57/14227/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14227/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/57/14227/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14227/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/57/14227?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Several treatments are available for women with cervical abnormalities, often referred to as dysplasia, CIN (cervical intraepithelial neoplasia) or CIS (carcinoma in situ). Treatments including cryosurgery (freezing), laser (high-energy light), and excision (surgical removal of the abnormal area).",
"    </p>",
"    <p>",
"     The tests performed to evaluate abnormal Pap smears are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"      \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHOOSING THE BEST TREATMENT FOR ABNORMAL PAP SMEARS",
"     </span>",
"    </p>",
"    <p>",
"     Abnormal pap smears are treated by identifying the area of abnormal cervical tissue and removing it to prevent worsening or spread to other areas of the cervix. There are two main types of treatment for cervical abnormalities:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Those that destroy the abnormal area (called ablative therapy) and",
"      </li>",
"      <li>",
"       Those that remove the abnormal areas (called excisional therapy).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some abnormalities are best treated with one type of treatment while others can be treated with either type, depending upon the patient and physician's preference. There are some classes of abnormalities that can be followed without treatment, if the physician and patient are willing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Excisional therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excisional therapies include loop electrosurgical excision procedures (LEEP), also called large loop excision of the transformation zone (LLETZ), laser conization, and cervical conization procedures. Most clinicians prefer excisional therapy (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Excision'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Excisional therapy is recommended when the extent or type of cervical abnormality is not clear based upon colposcopy and biopsy. In this situation, excision is preferred because the abnormal tissue can be examined with a microscope. This allows the physician to determine if the entire abnormal area was removed and if a more serious condition (eg, cervical cancer) is present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Ablative therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ablative therapies include cryosurgery and laser ablation. Ablative therapy may be recommended when there is less concern about cancer or about the extent of the abnormal tissue.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      EXCISION",
"     </span>",
"    </p>",
"    <p>",
"     Excision is a procedure that cuts out the abnormal area on the surface of the cervix; excision can also remove abnormalities that extend inside the cervical opening. Excision serves two purposes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       It provides a sample of tissue to confirm the degree of an abnormality and check for cancerous or precancerous cells deep within the cervix.",
"      </li>",
"      <li>",
"       Excision helps to ensure that the abnormality is removed completely. If the edges of the tissue that is removed show evidence of the abnormality or precancer, further treatment may be needed.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Loop electrosurgical excision procedure (LEEP)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excision can be done with a device that uses electrical current; this is called a LEEP procedure (loop electrosurgical excision procedure) or LLETZ (large loop excision of the transformation zone). A thin, wire loop is inserted through the vagina, where it uses an electric current to remove a cone-shaped portion of the cervix. This can also be performed with a laser knife, which uses high intensity energy from a light beam.",
"    </p>",
"    <p>",
"     Excision can be done in the office or operating room after the cervix is injected with local anesthesia to prevent pain. The woman may feel a dull ache or cramp during the procedure. A brown paste is applied after the treatment to prevent bleeding; this often causes a dark vaginal discharge (similar to coffee grounds). Most women are able to return to work or school after the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Cervical cone biopsy (conization)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Excision can also be done with a scalpel instead of a loop; this is called a cervical conization or cone biopsy (",
"     <a class=\"graphic graphic_figure graphicRef63427 \" href=\"UTD.htm?11/40/11906\">",
"      figure 1",
"     </a>",
"     ). Conization is usually done in an operating room after the patient has received general anesthesia (medicine given to induce sleep) or regional anesthesia (eg, epidural or spinal).",
"    </p>",
"    <p>",
"     Following LEEP or conization, most women have mild to moderate vaginal bleeding and discharge for one to two weeks. The bleeding should not be heavy (eg, should not soak a pad in less than one hour). Care after excision is described below (see",
"     <a class=\"local\" href=\"#H12\">",
"      'Post-procedure care'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;As with any surgical procedure, complications can occur during excision. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bleeding during the procedure &mdash; Bleeding is rarely serious, and can usually be managed with suturing or by applying cauterizing material (a liquid or treatment that helps the blood to clot) to the cervix.",
"      </li>",
"      <li>",
"       Bleeding after the procedure &mdash; Although light bleeding or spotting is normal, some women have heavy bleeding several days or weeks after the procedure. This can usually be treated in the office, but occasionally a procedure in an operating room is necessary.",
"      </li>",
"      <li>",
"       Infection &mdash; Infections occur rarely after cone biopsy, either on the cervix itself or elsewhere in the reproductive tract. Most infections can be treated with oral antibiotic therapy.",
"      </li>",
"      <li>",
"       Perforation of the uterus &mdash; This is an uncommon complication, and is more likely to occur in women who are postmenopausal or whose uterus is tipped forward. If the uterus is perforated, it usually heals without any need for treatment. Infrequently, laparoscopy or laparotomy is required to see and repair injuries to internal organs.",
"      </li>",
"      <li>",
"       Late complications &mdash; (see",
"       <a class=\"local\" href=\"#H16\">",
"        'Pregnancy after treatment for abnormal Pap smear'",
"       </a>",
"       below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ABLATIVE TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Ablative treatment destroy, rather then cut away, abnormal cervical tissue.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cryosurgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cryosurgery involves applying liquid nitrogen or carbon dioxide to the cervix. This causes the cervical tissue to freeze, which destroys the abnormal cells. Cryosurgery can be done in the office, similar to a pelvic examination, without any anesthesia. It may cause mild cramping or discomfort.",
"    </p>",
"    <p>",
"     Cryosurgery is not recommended in certain situations, such as when the extent and type of cervical abnormality are not clear based upon colposcopy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     biopsy. Excisional therapy is preferred in these cases.",
"    </p>",
"    <p>",
"     Most women have watery vaginal discharge for one week after cryosurgery. Care after cryosurgery is described below (see",
"     <a class=\"local\" href=\"#H12\">",
"      'Post-procedure care'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Laser ablation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laser ablation uses high intensity energy from a light beam to destroy abnormal areas of the cervix. The laser is directed to the abnormal area of the cervix through the vagina. This is usually performed in an operating room after the woman has received general anesthesia (medicine given to induce sleep) or regional anesthesia (eg, epidural or spinal). Laser treatment requires special training and equipment.",
"    </p>",
"    <p>",
"     A disadvantage of laser ablation is that it destroys the abnormal tissue, similar to cryosurgery. Laser ablation is not recommended in certain situations, such as when the extent and type of cervical abnormality are not clear based upon colposcopy",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     biopsy.",
"    </p>",
"    <p>",
"     Most women have vaginal discharge for one to two weeks after laser treatment. Care after laser treatment is described below (see",
"     <a class=\"local\" href=\"#H12\">",
"      'Post-procedure care'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      POST-PROCEDURE CARE",
"     </span>",
"    </p>",
"    <p>",
"     All women should ask about their ability to drive home from the procedure and when they can resume normal daily activities. Following treatment, most providers recommend avoiding sexual intercourse, not placing anything in the vagina (eg, douches, tampons), and not taking a bath or swim for a few weeks (showers are fine); other physicians may recommend a shorter period of \"pelvic rest\". This should be discussed in detail with the physician.",
"    </p>",
"    <p>",
"     In general, a woman should call her provider if she has bleeding that is heavier than a normal menstrual period (defined as soaking a pad in less than one hour, especially if there are clots), severe or worsening pain, fever over 101&ordm; F (38.4&ordm; C), or a foul-smelling vaginal discharge.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treatment efficacy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The treatments described above cure most women with abnormal cervical cells. Women that are not cured after a first treatment may have persistence, recurrence, or progression of the abnormality, especially if a high risk type of HPV (types 16 and 18) is present. Additional treatment is sometimes needed in this case. For this reason, lifelong follow up with cervical cytology smears (Pap smear) is important.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Follow up appointments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Typically, a woman is seen for a follow up examination several weeks after treatment to make sure the cervix is healing. A Pap smear (with or without colposcopy) is recommended approximately every six months. Colposcopy is recommended if atypical squamous cells or other abnormalities are found and HPV testing is positive. The time interval between subsequent tests will depend upon the results of the initial testing after treatment and the woman's age. Follow up is best discussed with a woman's individual provider since it may vary significantly from one woman to another.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Need for further treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some women will require additional treatments to ensure that all abnormal areas are removed. This is especially true if excision was done and microscopic analysis showed a larger abnormality than was expected. The decision to have additional treatment is individualized, based upon the type of abnormality seen, the woman's risk of cervical cancer, and whether or not childbearing is completed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"      \"Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PREGNANCY AFTER TREATMENT FOR ABNORMAL PAP SMEAR",
"     </span>",
"    </p>",
"    <p>",
"     Many women are concerned about the risks of infertility and preterm labor after being treated for an abnormal Pap smear. The risk of these complications depends upon a number of factors, including the type and number of treatment(s) performed (ablation versus excision) and the time between the treatment and the pregnancy. Other factors, such as underlying medical conditions and a woman's age can also increase a woman's risk of these conditions.",
"    </p>",
"    <p>",
"     Most women are advised to wait six to 12 months after conization before attempting to become pregnant to allow the tissue to heal fully. In general, the data suggest that excisional procedures slightly increase the risk of preterm delivery, but ablative procedures do not. The risk of infertility related to treatment is probably very small. More data are needed to better define these risks. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link&amp;anchor=H10#H10\">",
"      \"Patient information: Preterm labor (Beyond the Basics)\", section on 'Cervical length'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H171\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962312\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28163?source=see_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/8/15491?source=see_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962347\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/4/15429?source=see_link\">",
"      Patient information: Cervical cancer treatment; early stage cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=see_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Colposcopy and Cervical Pathology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asccp.org/\">",
"      www.asccp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     , search for HPV)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National HPV and Cervical Cancer Public Education Campaign",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Telephone: 1-866-280-6605",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cervicalcancercampaign.org/\">",
"      www.cervicalcancercampaign.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Social Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ashastd.org/\">",
"      file://www.ashastd.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/57/14227/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/57/14227?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14227/abstract/1\">",
"      Martin-Hirsch PL, Paraskevaidis E, Kitchener H. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2000; :CD001318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14227/abstract/2\">",
"      Matseoane S, Williams SB, Navarro C, et al. Diagnostic value of conization of the uterine cervix in the management of cervical neoplasia: a review of 756 consecutive patients. Gynecol Oncol 1992; 47:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14227/abstract/3\">",
"      G&ouml;k M, Coup&eacute; VM, Berkhof J, et al. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 2007; 104:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14227/abstract/4\">",
"      Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005; 331:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14227/abstract/5\">",
"      Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367:489.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_57_14227=[""].join("\n");
var outline_f13_57_14227=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHOOSING THE BEST TREATMENT FOR ABNORMAL PAP SMEARS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           EXCISION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ABLATIVE TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           POST-PROCEDURE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PREGNANCY AFTER TREATMENT FOR ABNORMAL PAP SMEAR",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/40/11906\" title=\"figure 1\">",
"           Cone biopsy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14228="p i concept";
var content_f13_57_14228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    The",
"    <em>",
"     p-i",
"    </em>",
"    concept of T cell activation in drug hypersensitivity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A drug may bind with a sufficiently high affinity to some of the many polymorphic T cell receptors (TCR) or HLA molecules.",
"    <br/>",
"    <ol>",
"     <li>",
"      The drug may fit into a certain TCR with sufficient affinity to initiate signaling by that cell. An additional interaction with the MHC molecule is required for full activation.",
"     </li>",
"     <li>",
"      The drug may bind preferentially to the MHC molecule. This binding may occur to certain HLA-alleles only, explaining the striking HLA association of some drug hypersensitivity reactions. The drug binding may alter the MHC molecule, and elicit a specific T cell response to the combination of HLA plus drug. Alternatively, the drug (eg, abacavir) may bind to the HLA-B*57:01 molecule and thereby alter the peptide-binding properties of this HLA-allele: Usual B*5701 binding peptides are displaced by other (novel) peptides. The presentation of new peptides may induce a kind of an autoimmune or alloimmune response.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"     SMX: sulfamethoxazole; MHC: major histocompatability complex.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified and updated for this publication. Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14228=[""].join("\n");
var outline_f13_57_14228=null;
var title_f13_57_14229="Neomycin: Drug information";
var content_f13_57_14229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/63/36852?source=see_link\">",
"    see \"Neomycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"    see \"Neomycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ammonium Detoxicant;",
"     </li>",
"     <li>",
"      Antibiotic, Aminoglycoside;",
"     </li>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative intestinal antisepsis:",
"     </b>",
"     Oral: 1 g each hour for 4 doses then 1 g every 4 hours for 5 doses; or 1 g at 1 PM, 2 PM, and 11 PM on day preceding surgery as an adjunct to mechanical cleansing of the bowel and oral erythromycin; or 6 g/day divided every 4 hours for 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatic encephalopathy:",
"     </b>",
"     Oral: 500-2000 mg every 6-8 hours or 4-12 g/day divided every 4-6 hours for 5-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatic insufficiency:",
"     </b>",
"     Oral: 4 g/day for an indefinite period",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=see_link\">",
"      see \"Neomycin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative intestinal antisepsis:",
"     </b>",
"     Oral: Children: 90 mg/kg/day divided every 4 hours for 2 days; or 25 mg/kg at 1 PM, 2 PM, and 11 PM on the day preceding surgery as an adjunct to mechanical cleansing of the intestine and in combination with erythromycin base",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatic encephalopathy:",
"     </b>",
"     Oral: Children: 50-100 mg/kg/day in divided doses every 6-8 hours or 2.5-7 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 4-6 hours for 5-6 days not to exceed 12 g/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Orally to prepare GI tract for surgery; treatment of diarrhea caused by",
"     <i>",
"      E. coli",
"     </i>",
"     ; adjunct in the treatment of hepatic encephalopathy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Nausea, diarrhea, vomiting, irritation or soreness of the mouth or rectal area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Dyspnea, eosinophilia, nephrotoxicity, neurotoxicity, ototoxicity (auditory), ototoxicity (vestibular)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin or any component of the formulation, or other aminoglycosides; intestinal obstruction, inflammatory or ulcerative gastrointestinal disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause nephrotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular blockade and respiratory paralysis:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis;",
"     </b>",
"     especially when given soon after anesthesia or muscle relaxants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: May cause neurotoxicity;",
"     </b>",
"     usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage.  Discontinue treatment if signs of ototoxicity occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal insufficiency; dosage modification required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral administration: More toxic than other aminoglycosides when given parenterally;",
"     <b>",
"      do not administer parenterally.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peritoneal lavage:",
"     <b>",
"      Do not use as peritoneal lavage",
"     </b>",
"     due to significant systemic adsorption of the drug.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoglycosides cross the placenta; however, neomycin has limited maternal absorption. Therefore the portion of an orally administered maternal dose available to cross the placenta is very low. Teratogenic effects have not been observed following maternal use of neomycin. Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy, the manufacturer classifies neomycin as pregnancy category D.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3183579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if neomycin is excreted into breast milk; however, limited oral absorption by both the mother and infant would minimize exposure to the nursing infant. Nondose-related effects could include modification of bowel flora. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Neomycin Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $136.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function tests, audiometry in symptomatic patients",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apokalin (NO);",
"     </li>",
"     <li>",
"      Biofradin (ES);",
"     </li>",
"     <li>",
"      Burn-Gel (ES);",
"     </li>",
"     <li>",
"      Bykomycin (AT, CZ, DE);",
"     </li>",
"     <li>",
"      Coliriocilina Neomicina (ES);",
"     </li>",
"     <li>",
"      Concatag (AR);",
"     </li>",
"     <li>",
"      Cysto-Myacyne N (DE);",
"     </li>",
"     <li>",
"      Endomixin (IT);",
"     </li>",
"     <li>",
"      Enteromicina (PT);",
"     </li>",
"     <li>",
"      Fradyl (BE, LU);",
"     </li>",
"     <li>",
"      Glubacida (MX);",
"     </li>",
"     <li>",
"      Minims Neomycin (BE, NL);",
"     </li>",
"     <li>",
"      Myacyne (DE);",
"     </li>",
"     <li>",
"      Mycifradin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nebacetin N Spruhverband (DE);",
"     </li>",
"     <li>",
"      Nebapol B (AR);",
"     </li>",
"     <li>",
"      Neo-Mix (AT);",
"     </li>",
"     <li>",
"      Neobiotic (ID);",
"     </li>",
"     <li>",
"      Neointestin (ES);",
"     </li>",
"     <li>",
"      Neomas (AR);",
"     </li>",
"     <li>",
"      Neomicina Estersa (ES);",
"     </li>",
"     <li>",
"      Neomicina Roger (ES);",
"     </li>",
"     <li>",
"      Neomicina Salvat (ES);",
"     </li>",
"     <li>",
"      Neomycin (IL);",
"     </li>",
"     <li>",
"      Neomycin Drossapharm (CH);",
"     </li>",
"     <li>",
"      Neomycine (BE);",
"     </li>",
"     <li>",
"      Neomycine Diamant (BE, FR, LU);",
"     </li>",
"     <li>",
"      Neomycine Minims (NL);",
"     </li>",
"     <li>",
"      Neomycinsulfat Chevita (AT);",
"     </li>",
"     <li>",
"      Neomycinum (PL);",
"     </li>",
"     <li>",
"      Neosulf (AU);",
"     </li>",
"     <li>",
"      Nivemycin (GB, IE);",
"     </li>",
"     <li>",
"      Ofodex (MX);",
"     </li>",
"     <li>",
"      Rovicine (CH);",
"     </li>",
"     <li>",
"      Sulfate de Neomycine-Chauvin (LU);",
"     </li>",
"     <li>",
"      Trioft&iacute;n (MX);",
"     </li>",
"     <li>",
"      Unguentum Neomycini (PL);",
"     </li>",
"     <li>",
"      Uro-Beniktol N (CH);",
"     </li>",
"     <li>",
"      Uro-Nebacetin N (DE);",
"     </li>",
"     <li>",
"      Vagicillin (DE);",
"     </li>",
"     <li>",
"      Vinacil (MX);",
"     </li>",
"     <li>",
"      Vitacilina (MX);",
"     </li>",
"     <li>",
"      Xyloderm (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, percutaneous: Poor (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 97% of an orally administered dose remains in the GI tract. Absorbed neomycin distributes to tissues and concentrates in the renal cortex. With repeated doses, accumulation also occurs in the inner ear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 0% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Slightly hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (age and renal function dependent): 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (97% of oral dose as unchanged drug); urine (30% to 50% of absorbed drug as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Begg EJ and Barclay ML, &ldquo;Aminoglycosides - 50 Years On,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1995, 39(6):597-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/57/14229/abstract-text/7654476/pubmed\" id=\"7654476\" target=\"_blank\">",
"        7654476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/57/14229/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edson RS and Terrell CL, &ldquo;The Aminoglycosides,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(11):1158-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/57/14229/abstract-text/1943249/pubmed\" id=\"1943249\" target=\"_blank\">",
"        1943249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feigin RD and Cherry JD,",
"      <i>",
"       Textbook of Pediatric Infectious Diseases",
"      </i>",
"      , 4th ed, Philadelphia, PA: WB Saunders Co, 1997.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9686 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14229=[""].join("\n");
var outline_f13_57_14229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709169\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200499\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200470\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200487\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200471\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200451\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200437\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200452\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200497\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200456\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200441\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200446\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200447\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722064\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200474\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3183579\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524688\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200449\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200458\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200440\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200455\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9686|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/63/36852?source=related_link\">",
"      Neomycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/42/29348?source=related_link\">",
"      Neomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14230="Diagnosis of hepatitis D virus infection";
var content_f13_57_14230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of hepatitis D virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Francesco Negro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14230/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/57/14230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatitis D virus (HDV, also called the delta virus) is a defective pathogen that requires the presence of the hepatitis B virus (HBV) for infection. The HD virion is composed of an outer lipoprotein envelope made of the surface antigen of the HBV (HBsAg) and an inner ribonucleoprotein structure in which the HDV genome resides. The HDV genome consists of a single stranded RNA which is folded as a rod-like structure through internal base-pairing (",
"    <a class=\"graphic graphic_figure graphicRef63575 \" href=\"UTD.htm?42/16/43279\">",
"     figure 1",
"    </a>",
"    ). It is complexed with the only HDV-encoded antigen, the HDAg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HDAg can elicit a specific immune response in the infected host, consisting of antibodies of the IgM and IgG class (anti-HDV). In HDV infected individuals, the timing of appearance and level of HDV RNA, HDAg, and anti-HDV in serum allow the three HDV-related clinical entities to be discriminated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute",
"      <span class=\"nowrap\">",
"       HBV/HDV",
"      </span>",
"      coinfection",
"     </li>",
"     <li>",
"      Acute HDV superinfection of a chronic HBV carrier",
"     </li>",
"     <li>",
"      Chronic HDV infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF HDV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the dependence of HDV on HBV, the presence of HBsAg is necessary for the diagnosis of HDV infection. The additional presence of IgM antibody to hepatitis B core antigen (IgM anti-HBc) is necessary for the diagnosis of acute",
"    <span class=\"nowrap\">",
"     HBV/HDV",
"    </span>",
"    coinfection (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Detection of serum HDAg",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum HDAg can be detected by microplate-based, enzyme-linked (EIA) or radioimmunoassays (RIA). At present, these assays are not available for clinical diagnosis in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In acute HDV infection, serum HDAg appears early but is very short-lived and may escape detection if repeated testing is not performed (",
"      <a class=\"graphic graphic_figure graphicRef60216 \" href=\"UTD.htm?10/48/11022\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/2-5\">",
"       2-5",
"      </a>",
"      ]. In one study on 18 patients, for example, serum HDAg was demonstrated in 39 percent of patients with acute",
"      <span class=\"nowrap\">",
"       HBV/HDV",
"      </span>",
"      coinfection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/3\">",
"       3",
"      </a>",
"      ]. HDAg lasts longer when the immune response is slow and weak as in immunodeficient individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In chronic HDV infection, anti-HDV is present in high titers. Thus, HDAg cannot be detected by microwell assays since it is complexed with anti-HDV. Serum HDAg is best detected in this setting by immunoblot assay [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/7\">",
"       7",
"      </a>",
"      ], since polyacrylamide gel electrophoresis under denaturing conditions allows separation of HDAg from anti-HDV. Immunoblot assay is very sensitive [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/8\">",
"       8",
"      </a>",
"      ] but technically difficult, time- and labor-consuming, and cannot be used for routine detection of HDAg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Detection of serum HDV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDV RNA can be detected in serum by either molecular hybridization or reverse transcriptase-polymerase chain reaction (RT-PCR) based assays (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hybridization assays using riboprobe have a detection limit of about 10(4) to 10(6) genomes per mL [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]. Using this approach, HDV RNA was shown to be an early and sensitive marker of HDV replication in acute hepatitis D [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/10\">",
"       10",
"      </a>",
"      ]. However, in chronic HDV infection, comparative studies were only able to detect HDV RNA in the serum of 70 to 80 percent of patients who had positive staining for HDAg in liver tissue, underscoring the limited sensitivity of hybridization assays. These have now been superseded by PCR assays.",
"     </li>",
"     <li>",
"      RT-PCR assays have a detection limit of less than 10 genomes per mL [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/12-16\">",
"       12-16",
"      </a>",
"      ]. However, the extensive sequence heterogeneity of different HDV isolates makes it difficult to choose suitable primers for the amplification of HDV RNA since only a few conserved regions exist in the HDV genome. Furthermore, the secondary and tertiary structure of the HDV RNA may hamper efficient amplification even of highly conserved regions [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/15\">",
"       15",
"      </a>",
"      ]. The best efficiency is obtained by amplifying the C-terminal half of the HDAg-encoding region [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/15\">",
"       15",
"      </a>",
"      ]. A microwell-based EIA using an anti-double-stranded DNA monoclonal antibody to detect HDV amplicons is commercially available in some countries [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Novel, automated assays are being established to allow the monitoring of HDV RNA kinetics in the serum of infected patients during treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RT-PCR assays for HDV RNA can also be used to assess the eradication of HDV infection in patients with remission of liver disease following the administration of interferon alpha and in patients who have no serological evidence of HDV reinfection after liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/19\">",
"       19",
"      </a>",
"      ]. Serum HDV RNA can be detected by RT-PCR in about one-third of patients who have spontaneous remission of HDV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An interesting application of the RT-PCR assay for serum HDV RNA is the analysis of the different HDV genotypes. Genotyping can be performed by direct sequencing or restriction fragment length polymorphism of the amplicon [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. Since the clinical relevance of HDV genotyping is uncertain, its widespread use is at present not recommended. Furthermore, the phylogenetic classification of the various HDV genotypes is currently debated [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sequence analysis of semi-conserved regions of HDV RNA can be used to detect common sources of infection such as after intrafamilial or perinatal transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Detection of anti-HDV antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total (IgM and IgG) anti-HDV antibodies can be detected by EIAs or RIAs (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ). These are the only commercially available assays for the diagnosis of HDV infection in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total anti-HDV antibody appears usually after four weeks of acute infection in acute hepatitis D (",
"      <a class=\"graphic graphic_figure graphicRef60216 \" href=\"UTD.htm?10/48/11022\">",
"       figure 2",
"      </a>",
"      ). As a result, its clinical value is limited unless repeated testing is performed [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/2,5\">",
"       2,5",
"      </a>",
"      ]. Nevertheless, a well documented anti-HDV seroconversion may be the only way to diagnose acute HDV infection in the absence of other markers of HDV infection.",
"     </li>",
"     <li>",
"      High-titer anti-HDV of the IgG class is present in chronic HDV infection. It correlates well with ongoing HDV replication and may help in differentiating current from past HDV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-HDV of the IgM class can be detected by EIAs or RIAs, but these assays are not available for clinical use in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/27\">",
"       27",
"      </a>",
"      ]. IgM anti-HDV is transient and delayed if the course of acute hepatitis D is self-limited, but it may be the only serum marker of acute HDV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/2\">",
"       2",
"      </a>",
"      ]. In patients who progress to chronic HDV infection, which is usually the case in those with HDV superinfection, IgM anti-HDV is brisk and long-lasting. It should be remembered, however, that differentiating between",
"      <span class=\"nowrap\">",
"       HBV/HDV",
"      </span>",
"      coinfection and HDV superinfection in an HBV carrier relies mainly on the detection of high-titer IgM anti-HBc in patients with coinfection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IgM anti-HDV is present in high titers during chronic HDV infection, and the titers correlate with the level of HDV replication and severity of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/27\">",
"     27",
"    </a>",
"    ]. IgM anti-HDV gradually disappears from serum in patients who have persistent remission after interferon therapy and following liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tissue markers of HDV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both HDAg and HDV RNA can be detected in liver tissues routinely processed for histopathologic evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HDAg can be detected by direct immunofluorescence or immunohistochemical staining. The detection of intrahepatic HDAg has been proposed as the \"gold\" standard for the diagnosis of current HDV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/29\">",
"       29",
"      </a>",
"      ]. However, as many as 50 percent of liver biopsy specimens from patients who have been infected for 10 or more years may be negative for HDAg, suggesting that the levels of HDV replication may decrease with time [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/16,30\">",
"       16,30",
"      </a>",
"      ]. In patients who are negative for HDAg, the diagnosis of current HDV infection has to rely on the detection of HDV RNA and high-titer anti-HDV antibodies in the serum.",
"     </li>",
"     <li>",
"      HDV RNA can be detected by in-situ hybridization. However, the techniques involved are too time-consuming, tedious, and difficult for clinical use [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14230/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the dependence of HDV on HBV, the diagnosis of hepatitis D cannot be made in the absence of markers of HBV infection. The diagnosis of HDV infection should be considered in the following clinical situations (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute hepatitis B virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute HBV infection, testing for HDV coinfection should be considered in those who have risk factors (intravenous drug users and patients from endemic countries) or who present with unusually severe or protracted hepatitis. Patients should be positive for HBsAg and have high titer IgM anti-HBc. However, markers of HBV replication may precede or follow those of HDV. In addition, occasional patients have already seroconverted to anti-HBs if they present during the second phase of biphasic hepatitis. These patients should still be positive for high-titer IgM anti-HBc (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Serum HDAg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HDV RNA are usually positive at presentation. If assays for serum HDAg or HDV RNA are not available, repeated testing for anti-HDV (total or IgM) should be performed to document anti-HDV seroconversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute hepatitis of undetermined origin in a chronic HBV carrier",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests for HDV should be considered to rule out acute HDV superinfection in this setting. Since HDV superinfection may occur in previously unrecognized chronic HBV carriers, distinguishing between this condition and acute",
"    <span class=\"nowrap\">",
"     HBV/HDV",
"    </span>",
"    coinfection can be difficult. This distinction is important because of the differences in prognosis (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBsAg is present in both situations, but IgM anti-HBc should be negative in acute HDV superinfection (",
"      <a class=\"graphic graphic_figure graphicRef54793 \" href=\"UTD.htm?21/46/22254\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The diagnosis is made more difficult since HDV superinfection may cause transient suppression of HBV replication, resulting in very low and, rarely, undetectable levels of HBsAg.",
"     </li>",
"     <li>",
"      As in patients with acute",
"      <span class=\"nowrap\">",
"       HBV/HDV",
"      </span>",
"      coinfection, patients with acute HDV superinfection are usually positive for HDAg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HDV RNA in serum at the time of presentation. However, in contrast to acute coinfection, acute HDV superinfection is characterized by persistent detection of HDV RNA in serum and rapidly increasing titers of anti-HDV (total and IgM).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HBsAg-positive chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests for HDV should be considered in such patients to rule out coexistent chronic HDV infection. This is best achieved by screening for total anti-HDV antibody. The presence of chronic HDV infection can be confirmed by immunohistochemical staining for HDAg in liver tissues. Measurement of serum HDV RNA should be performed in patients who are anti-HDV positive but have no detectable HDAg in the liver or to evaluate the indications and effects of antiviral therapy. In chronic HDV infection, markers of HBV replication are usually absent, and the patient is typically HBeAg negative and anti-HBe-positive. However, HDV RNA and HBV DNA may occasionally coexist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     When and how to test for HDV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries such as the United States where HDV infection is rare, testing for HDV infection is not necessary in all patients with HBV infection. By contrast, testing should be performed in patients who emigrated from countries with a high prevalence of HDV infection (such as Eastern European countries, Mediterranean countries, and countries in Central America) as well as those who had a history of injection drug use. Patients in countries with high or intermediate HDV endemicity should be tested for HDV infection prior to antiviral treatment.",
"   </p>",
"   <p>",
"    Initial testing is often limited to total anti-HDV, which is often the only blood test available. When possible, the diagnosis should be confirmed by immunohistochemical staining of liver biopsies for HDAg or by RT-PCR assays for HDV RNA in serum. A negative test for total anti-HDV does not necessarily exclude a diagnosis of acute",
"    <span class=\"nowrap\">",
"     HBV/HDV",
"    </span>",
"    coinfection (",
"    <a class=\"graphic graphic_table graphicRef52583 \" href=\"UTD.htm?42/58/43947\">",
"     table 1",
"    </a>",
"    ). Furthermore, HDAg may not be detectable in liver biopsies in patients with chronic HDV infection, particularly during the late stages.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/1\">",
"      Taylor J, Negro F, Rizzetto M. Hepatitis delta virus: From structure to disease expression. Rev Med Virol 1992; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/2\">",
"      Aragona M, Macagno S, Caredda F, et al. Serological response to the hepatitis delta virus in hepatitis D. Lancet 1987; 1:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/3\">",
"      Govindarajan S, Valinluck B, Peters L. Relapse of acute B viral hepatitis--role of delta agent. Gut 1986; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/4\">",
"      Shattock AG, Morgan BM. Sensitive enzyme immunoassay for the detection of delta antigen and anti-delta, using serum as the delta antigen source. J Med Virol 1984; 13:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/5\">",
"      Buti M, Esteban R, Jard&iacute; R, et al. Serological diagnosis of acute delta hepatitis. J Med Virol 1986; 18:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/6\">",
"      Grippon P, Ribiere O, Cadranel JF, et al. Long-term delta antigenaemia without appearance of delta antibody in two immunodeficient patients. Lancet 1987; 1:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/7\">",
"      Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 1986; 58:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/8\">",
"      Buti M, Esteban R, Jardi R, et al. Chronic delta hepatitis: detection of hepatitis delta virus antigen in serum by immunoblot and correlation with other markers of delta viral replication. Hepatology 1989; 10:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/9\">",
"      Negro F, Bergmann KF, Baroudy BM, et al. Chronic hepatitis D virus (HDV) infection in hepatitis B virus carrier chimpanzees experimentally superinfected with HDV. J Infect Dis 1988; 158:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/10\">",
"      Buti M, Esteban R, Roggendorf M, et al. Hepatitis D virus RNA in acute delta infection: serological profile and correlation with other markers of hepatitis D virus infection. Hepatology 1988; 8:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/11\">",
"      Zignego AL, Dubois F, Samuel D, et al. Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. J Hepatol 1990; 11:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/12\">",
"      Zignego AL, Deny P, Feray C, et al. Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning. Mol Cell Probes 1990; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/13\">",
"      Madej&oacute;n A, Castillo I, Bartolom&eacute; J, et al. Detection of HDV-RNA by PCR in serum of patients with chronic HDV infection. J Hepatol 1990; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/14\">",
"      Cariani E, Ravaggi A, Puoti M, et al. Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. Hepatology 1992; 15:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/15\">",
"      Dinolfo L, Abate ML, Bertolo P, et al. Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay. Int J Clin Lab Res 1995; 25:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/16\">",
"      Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/17\">",
"      Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/18\">",
"      Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/19\">",
"      Negro F, Rizzetto M. Diagnosis of hepatitis delta virus infection. J Hepatol 1995; 22:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/20\">",
"      Casey JL, Brown TL, Colan EJ, et al. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993; 90:9016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/21\">",
"      Wu JC, Choo KB, Chen CM, et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995; 346:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/22\">",
"      Casey JL, Niro GA, Engle RE, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis 1996; 174:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/23\">",
"      Niro GA, Smedile A, Andriulli A, et al. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997; 25:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/24\">",
"      D&eacute;ny P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol 2006; 307:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/25\">",
"      Niro GA, Casey JL, Gravinese E, et al. Intrafamilial transmission of hepatitis delta virus: molecular evidence. J Hepatol 1999; 30:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/26\">",
"      Huang YH, Wu JC, Lu SN, et al. Phylogenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/27\">",
"      Smedile A, Lavarini C, Crivelli O, et al. Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:\" clinical significance in delta infection. J Med Virol 1982; 9:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/28\">",
"      Borghesio E, Rosina F, Smedile A, et al. Serum immunoglobulin M antibody to hepatitis D as a surrogate marker of hepatitis D in interferon-treated patients and in patients who underwent liver transplantation. Hepatology 1998; 27:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14230/abstract/29\">",
"      Di Bisceglie AM, Negro F. Diagnosis of hepatitis delta virus infection. Hepatology 1989; 10:1014.",
"     </a>",
"    </li>",
"    <li>",
"     Bonino F, Negro F, Baldi M, et al. The natural history of chronic delta hepatitis. In: The hepatitis delta virus and its infection, Rizzetto M, Gerin JL, Purcell RH (Eds), Alan R Liss, New York 1987. p.145.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3662 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14230=[""].join("\n");
var outline_f13_57_14230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF HDV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Detection of serum HDAg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Detection of serum HDV RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Detection of anti-HDV antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tissue markers of HDV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute hepatitis of undetermined origin in a chronic HBV carrier",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HBsAg-positive chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      When and how to test for HDV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3662|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/16/43279\" title=\"figure 1\">",
"      HDV virion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/48/11022\" title=\"figure 2\">",
"      Serum markers acute HBV HDV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/46/22254\" title=\"figure 3\">",
"      Acute HDV in chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/58/43947\" title=\"table 1\">",
"      Diagnosis of hepatitis D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=related_link\">",
"      Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14231="Lymphocytic gastritis Light";
var content_f13_57_14231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphocytic gastritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph of a gastric biopsy from a patient with lymphocytic gastritis. The dilated pits are separated by a cellular lamina propria containing a mixture of plasma cells and lymphocytes. The epithelium covering the surface and the superficial pits is disorganized and contains lymphocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14231=[""].join("\n");
var outline_f13_57_14231=null;
var title_f13_57_14232="Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection";
var content_f13_57_14232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14232/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/57/14232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterohemorrhagic E. coli (EHEC) are strains capable of producing Shiga toxin and typically cause bloody diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Hemolytic-uremic syndrome (HUS) complicates 6 to 9 percent of EHEC infections overall, and about 15 percent of EHEC infections in children under age 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Since the initial recognition of severe bloody diarrhea due to E. coli O157:H7 in the United States in 1982, outbreaks and sporadic infections have been attributed to EHEC worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4-21\">",
"     4-21",
"    </a>",
"    ]. In May 2011, a new Shiga toxin-producing EHEC strain, O104:H4, was identified as the cause of an outbreak in Germany and other countries in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of EHEC will be reviewed here. The microbiology, pathogenesis, epidemiology, and prevention of EHEC infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=see_link\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period between exposure to Enterohemorrhagic E. coli (EHEC) and the onset of symptoms is typically three to four days (range one to nine days) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/10\">",
"     10",
"    </a>",
"    ]. Clinical manifestations may include history of bloody diarrhea, a visibly bloody stool specimen, no reported fever, a peripheral white blood cell count above",
"    <span class=\"nowrap\">",
"     10,000/microL,",
"    </span>",
"    and abdominal tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/3,10,24\">",
"     3,10,24",
"    </a>",
"    ]. In one large series, three or more of these features were present in 65 percent of patients with E. coli O157:H7 infection (compared with 19 percent of those with infection due to Shigella, Campylobacter, or Salmonella) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemolytic-uremic syndrome is a major complication of EHEC infection, discussed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Hemolytic-uremic syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hospitalization is required in 23 to 47 percent of symptomatic patients with acute diarrhea due to EHEC, with a median hospital stay of 6 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. The mortality rate is generally 1 to 2 percent, although it may be substantially higher among the elderly and among patients with HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. Uncomplicated EHEC infection generally resolves in approximately one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7485212\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common manifestation following infection with EHEC is hemorrhagic colitis. In one study of more than 30,000 stool specimens, 63 percent of E. coli O157:H7 isolates came from visibly bloody specimens, and 91 percent of these patients gave a history of bloody diarrhea at some time during their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/10\">",
"     10",
"    </a>",
"    ]. Other pathogens isolated less frequently from patients with bloody diarrhea included Shigella, Campylobacter, and Salmonella spp (15, 8, and 5 percent, respectively). Another study of 873 patients with bloody diarrhea noted that E. coli O157:H7 accounted for only 10 percent of isolates from visibly bloody specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/24\">",
"     24",
"    </a>",
"    ]. The factors responsible for the difference between these studies are uncertain.",
"   </p>",
"   <p>",
"    Initially, EHEC infection may also cause nonbloody diarrhea; however, in some reports, approximately half of patients with EHEC infection and nonbloody diarrhea progress to bloody diarrhea during the course of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-O157 EHEC strains may also cause severe illness, particularly the O104:H4 identified initially in Germany in May 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Prior to this outbreak, reports from the United States and Canada reported a lower frequency of bloody diarrhea due to non-O157 EHEC than due to E. coli O157:H7 (58 versus 81 percent and 42 versus 97 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemolytic-uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic-uremic syndrome (HUS) is the major systemic complication of EHEC infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/30\">",
"     30",
"    </a>",
"    ]. HUS is characterized by the triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia; these typically begin 5 to 10 days after the onset of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who also have fever and neurologic symptoms are considered to have the related disorder thrombotic thrombocytopenic purpura (TTP), some cases of which have also been associated with E. coli O157:H7 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HUS generally complicates 6 to 9 percent of EHEC infections overall and about 15 percent of EHEC infections in children under age 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/3-5,19\">",
"     3-5,19",
"    </a>",
"    ]. However, a higher proportion of cases in the May 2011 outbreak of O104:H4 infection in Germany have been complicated by HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In this outbreak, 22 percent of cases were associated with HUS, 88 percent of the infected patients in this outbreak were 18 years of age or older, and more&nbsp;than 60 percent&nbsp;were female.",
"   </p>",
"   <p>",
"    In 2008, a total of 64 cases of postdiarrheal HUS were reported in the United States; of these, approximately two-thirds occurred among children less than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/31\">",
"     31",
"    </a>",
"    ]. HUS is the most common cause of acute renal failure in children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4,6,9\">",
"     4,6,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who develop HUS, up to 50 percent require dialysis during the acute phase; mortality is 3 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/4,9,32-34\">",
"     4,9,32-34",
"    </a>",
"    ]. Long-term renal sequelae (hypertension, proteinuria, reduced glomerular filtration rate) have been observed in up to 39 percent of patients, and neurologic sequelae (seizures, stroke, coma, motor deficits) in 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ]. Pathologic examination may demonstrate thrombi in glomerular arterioles (",
"    <a class=\"graphic graphic_picture graphicRef68492 \" href=\"UTD.htm?0/44/709\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrointestinal illness due to E. coli O157:H7 among adults has also been associated with long-term systemic effects, including hypertension (Relative Risk [RR] 1.3, 95% CI 1.1&ndash;1.5) and renal impairment (RR 3.4, 95% CI 1.5-7.7), even in the absence of HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been estimated that EHEC is associated with at least 70 percent of cases of postdiarrheal HUS in the United States, and of these cases, 80 percent are caused by E. coli O157:H7 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, the majority of cases of postdiarrheal HUS in Australia are due to non-O157 Shiga toxin producing E. coli; O157 infections are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/20\">",
"     20",
"    </a>",
"    ]. Non-O157 strains have also been linked to HUS in other countries, including 43 percent of cases in Germany and Austria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/26,38\">",
"     26,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5636939\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic investigations of outbreaks have suggested that some culture-positive individuals are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, two cases of chronic diarrhea due to EHEC infection have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/40\">",
"     40",
"    </a>",
"    ]. Pseudomembranous colitis has been reported as a rare manifestation of E. coli O157:H7 infection (in the absence of Clostridium difficile infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterohemorrhagic E. coli (EHEC) infection should be suspected in patients with acute bloody diarrhea, or hemolytic-uremic syndrome, particularly if associated with abdominal tenderness and the absence of fever [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/10\">",
"     10",
"    </a>",
"    ]. should also be suspected in individuals with recent epidemiologic exposure to regions with active outbreak activity (such as individuals with travel to Germany during the E. coli O104:H4 outbreak) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach to establishing the diagnosis of HUS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6412743\">",
"    <span class=\"h2\">",
"     E. coli O157:H7",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for E. coli O157:H7 in stool may be performed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    -MacConkey (SMAC) agar, as the organism ferments sorbitol slowly. Sorbitol-negative (translucent) colonies can be confirmed as E. coli biochemically and then tested for reaction with antisera to the O157 antigen. Strains presumptively identified as E. coli O157:H7 should be sent to a reference laboratory for confirmation.",
"   </p>",
"   <p>",
"    The likelihood of organism detection is highest in the first six days after onset of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/42\">",
"     42",
"    </a>",
"    ]. Some clinical laboratories in the United States screen all liquid stool samples for E. coli O157:H7, some screen bloody stools, and others screen only upon request from a treating clinician. The United States Centers for Disease Control and Prevention (CDC) recommends that all stools submitted for culture be screened for E. coli O157:H7. However, since more than 90 percent of cultures positive for E. coli O157:H7 come from patients with visibly bloody stools or a history of bloody diarrhea, it is reasonable to preferentially screen bloody stools for 0157:H7.",
"   </p>",
"   <p>",
"    Newer diagnostic techniques for EHEC infection focus on direct detection of Shiga toxins in stool, or the use of DNA probes for detecting the toxin genes in fecal isolates. Enzyme-linked immunosorbent assays detect both Shiga toxin 1 and Shiga toxin 2 in stool [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Occasional false positive results occur with direct detection of Shiga toxin or toxin genes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/45\">",
"     45",
"    </a>",
"    ]. In addition, these assays do not identify the serotype of the strain, which is important for tracing the source of infection in outbreaks. For these reasons, the CDC recommends both strain isolation using cultures and direct detection of Shiga toxins in stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6412751\">",
"    <span class=\"h2\">",
"     E. coli O104:H4",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States public health surveillance systems are able to identify O104:H4 as well as other rare Shiga toxin-producing E. coli (STEC) strains; the ability to detect STEC infections depends on proper diagnostic testing of patients presenting with symptoms suggestive of STEC infection. The diagnosis may be established directly (via toxin detection) or indirectly (via serologic detection), in the setting of a positive result for at least one of the following four tests [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation of E. coli from stool AND detection of Shiga toxin via enzyme-linked immunosorbent assay (ELISA)",
"     </li>",
"     <li>",
"      Mixed culture of E. coli and other pathogens from stool AND detection of a Shiga toxin gene via polymerase chain reaction (PCR)",
"     </li>",
"     <li>",
"      Detection of anti-LPS IgM antibodies against an appropriate E. coli serogroup, such as O104, via ELISA or Western blot",
"     </li>",
"     <li>",
"      A fourfold or greater change in the concentration of anti-LPS IgG antibodies against an appropriate E. coli serogroup, such as O104, between acute and convalescent samples",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of Enterohemorrhagic E. coli (EHEC) infection consists of supportive care and monitoring for the development of microangiopathic complications, such as HUS. Antiperistaltic agents increase the risk of systemic complications and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20808880\">",
"    <span class=\"h2\">",
"     Role of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is generally not beneficial in patients with EHEC infection. Antibiotic therapy did not alter the duration of acute illnesses in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], and in experimental studies, antibiotic therapy has been observed to induce the expression and release of Shiga toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Several studies have shown correlation between antibiotic use and risk for HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/25,54-57\">",
"     25,54-57",
"    </a>",
"    ], including one large prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/57\">",
"     57",
"    </a>",
"    ]. Among 259 children &lt;10 years of age with E. coli O157:H7 infection, hemolytic-uremic syndrome (HUS) occurred more frequently in the 25 children who received antibiotics, which included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , beta-lactams,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (36 compared with 12 percent in those who did not receive antibiotics) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/57\">",
"     57",
"    </a>",
"    ]. After adjustment for other variables, the absolute antibiotic-attributable risk increase for HUS incidence was 25 percent, corresponding to one case of HUS for every four children treated with antibiotics.",
"   </p>",
"   <p>",
"    Retrospective data from the German E. coli O104:H4 outbreak in 2011 suggested that antibiotic therapy was associated with shortening of Shiga toxin-producing E. coli (STEC) fecal excretion, seizure incidence, and death, and there was no clinical evidence suggestive of antibiotic induced toxin release [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/58\">",
"     58",
"    </a>",
"    ]. However, most patients did not receive antibiotics and the study was not randomized.",
"   </p>",
"   <p>",
"    As antibiotic therapy has not been shown conclusively to alter the course of acute diarrhea, we favor stopping antibiotics if they were started empirically prior to microbiological results, and we favor not using antibiotic therapy in children &lt;10 years of age if EHEC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HUS are clinically suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20808907\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeting the toxin directly has been proposed as an alternative therapeutic intervention, using hyperimmune antitoxin antisera or oral toxin-binding agents to reduce toxin absorption from the gut lumen. These approaches remain experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14232/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to management of HUS in the setting of EHEC infection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/63/31730?source=see_link\">",
"       \"Patient information: E. coli (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4451659\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enterohemorrhagic E. coli (EHEC) are strains capable of producing Shiga toxin and typically cause bloody diarrhea. The incubation period between exposure to EHEC and the onset of symptoms is typically three to four days (range one to nine days). Clinical manifestations may include history of bloody diarrhea, a visibly bloody stool specimen, no reported fever, a peripheral white blood cell count above",
"      <span class=\"nowrap\">",
"       10,000/microL,",
"      </span>",
"      and abdominal tenderness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemolytic-uremic syndrome (HUS) is the major systemic complication of EHEC infection. HUS is characterized by the triad of acute renal failure, microangiopathic hemolytic anemia, and thrombocytopenia; these typically begin 5 to 10 days after the onset of diarrhea. Patients who also have fever and neurologic symptoms are considered to have the related disorder thrombotic thrombocytopenic purpura (TTP), some cases of which have also been associated with E. coli O157:H7 infection. HUS generally complicates 6 to 9 percent of EHEC infections overall and about 15 percent of EHEC infections in children under age 10; for reasons that are not yet known, the incidence of HUS was substantially higher in the outbreak of E. coli O104:H4 infection in Europe in the summer of 2011. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hemolytic-uremic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for E. coli O157:H7 in stool may be performed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      -MacConkey (SMAC) agar, as the organism ferments sorbitol slowly. Sorbitol-negative (translucent) colonies can be confirmed as E. coli biochemically and then tested for reaction with antisera to the O157 antigen. Strains presumptively identified as E. coli O157:H7 should be sent to a reference laboratory for confirmation. The likelihood of organism detection is highest in the first six days after onset of diarrhea. (See",
"      <a class=\"local\" href=\"#H6412743\">",
"       'E. coli O157:H7'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct detection of toxin or toxin genes in the stool is more sensitive than SMAC agar and can detect non-O157:H7 Shiga toxin-producing E. coli (STEC) strains; testing by both culture and toxin assay is recommended by the United States Centers for Disease Control and Prevention. The diagnosis of E. coli O104:H4 infection may be established directly (via toxin detection) or indirectly (via serologic detection).",
"     </li>",
"     <li>",
"      The treatment of EHEC infection consists of supportive care and monitoring for the development of microangiopathic complications. We recommend NOT administering antibiotic therapy to patients with EHEC infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For situations in which EHEC is suspected, antibiotics should be withheld pending diagnostic information, particularly in children under the age of 10. For circumstances in which antibiotic therapy was initiated empirically, it should be discontinued if diagnostic data demonstrating EHEC become available. Antibiotics have not been observed to alter the duration of acute diarrhea, can induce the expression and release of Shiga toxin, and may increase the risk of HUS in children. Antiperistaltic agents increase the risk of systemic complications and should also be avoided. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to diagnosis and management of HUS in children and adults is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=see_link\">",
"       \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/1\">",
"      Levine MM. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987; 155:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/2\">",
"      O'Brien AO, Lively TA, Chen ME, et al. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet 1983; 1:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/3\">",
"      Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/4\">",
"      Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/5\">",
"      Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/6\">",
"      Su C, Brandt LJ. Escherichia coli O157:H7 infection in humans. Ann Intern Med 1995; 123:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/7\">",
"      Waters JR, Sharp JC, Dev VJ. Infection caused by Escherichia coli O157:H7 in Alberta, Canada, and in Scotland: a five-year review, 1987-1991. Clin Infect Dis 1994; 19:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/8\">",
"      Tarr PI. Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin Infect Dis 1995; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/9\">",
"      No&euml;l JM, Boedeker EC. Enterohemorrhagic Escherichia coli: a family of emerging pathogens. Dig Dis 1997; 15:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/10\">",
"      Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/11\">",
"      Dundas S, Todd WT, Stewart AI, et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/12\">",
"      Slutsker L, Ries AA, Maloney K, et al. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998; 177:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/13\">",
"      Jay MT, Garrett V, Mohle-Boetani JC, et al. A multistate outbreak of Escherichia coli O157:H7 infection linked to consumption of beef tacos at a fast-food restaurant chain. Clin Infect Dis 2004; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/14\">",
"      Cody SH, Glynn MK, Farrar JA, et al. An outbreak of Escherichia coli O157:H7 infection from unpasteurized commercial apple juice. Ann Intern Med 1999; 130:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/15\">",
"      Fukushima H, Hashizume T, Morita Y, et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int 1999; 41:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Escherichia coli O157:H7 infection associated with drinking raw milk--Washington and Oregon, November-December 2005. MMWR Morb Mortal Wkly Rep 2007; 56:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/17\">",
"      Crump JA, Sulka AC, Langer AJ, et al. An outbreak of Escherichia coli O157:H7 infections among visitors to a dairy farm. N Engl J Med 2002; 347:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/18\">",
"      Varma JK, Greene KD, Reller ME, et al. An outbreak of Escherichia coli O157 infection following exposure to a contaminated building. JAMA 2003; 290:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/19\">",
"      Bender JB, Hedberg CW, Besser JM, et al. Surveillance by molecular subtype for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping. N Engl J Med 1997; 337:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/20\">",
"      Elliott EJ, Robins-Browne RM, O'Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 85:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Multistate outbreak of Escherichia coli O157:H7 infections associated with eating ground beef--United States, June-July 2002. MMWR Morb Mortal Wkly Rep 2002; 51:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/22\">",
"      Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/23\">",
"      Buchholz U, Bernard H, Werber D, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/24\">",
"      Talan D, Moran GJ, Newdow M, et al. Etiology of bloody diarrhea among patients presenting to United States emergency departments: prevalence of Escherichia coli O157:H7 and other enteropathogens. Clin Infect Dis 2001; 32:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/25\">",
"      Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. N Engl J Med 1987; 317:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/26\">",
"      Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis 2006; 43:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/27\">",
"      Pai CH, Ahmed N, Lior H, et al. Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study. J Infect Dis 1988; 157:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/28\">",
"      Jelacic JK, Damrow T, Chen GS, et al. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J Infect Dis 2003; 188:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/29\">",
"      Werber D, Fruth A, Heissenhuber A, et al. Shiga toxin-producing Escherichia coli O157 more frequently cause bloody diarrhea than do non-O157 strains. J Infect Dis 2004; 189:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/30\">",
"      Karmali MA, Petric M, Lim C, et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food - 10 states, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/32\">",
"      Siegler RL, Milligan MK, Burningham TH, et al. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr 1991; 118:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/33\">",
"      Fitzpatrick MM, Shah V, Trompeter RS, et al. Long term renal outcome of childhood haemolytic uraemic syndrome. BMJ 1991; 303:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/34\">",
"      Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet 1998; 352:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/35\">",
"      Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/36\">",
"      Clark WF, Sontrop JM, Macnab JJ, et al. Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study. BMJ 2010; 341:c6020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/37\">",
"      Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/38\">",
"      Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/39\">",
"      Stephan R, Untermann F. Virulence factors and phenotypical traits of verotoxin-producing Escherichia coli strains isolated from asymptomatic human carriers. J Clin Microbiol 1999; 37:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/40\">",
"      Spacek LA, Hurley BP, Acheson DW, et al. Shiga toxin-producing Escherichia coli as a possible etiological agent of chronic diarrhea. Clin Infect Dis 2004; 39:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/41\">",
"      Kendrick JB, Risbano M, Groshong SD, Frankel SK. A rare presentation of ischemic pseudomembranous colitis due to Escherichia coli O157:H7. Clin Infect Dis 2007; 45:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/42\">",
"      Tarr PI, Neill MA, Clausen CR, et al. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990; 162:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/43\">",
"      Mackenzie AM, Lebel P, Orrbine E, et al. Sensitivities and specificities of premier E. coli O157 and premier EHEC enzyme immunoassays for diagnosis of infection with verotxin (Shiga-like toxin)-producing Escherichia coli. The SYNSORB Pk Study investigators. J Clin Microbiol 1998; 36:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/44\">",
"      Kehl KS, Havens P, Behnke CE, Acheson DW. Evaluation of the premier EHEC assay for detection of Shiga toxin-producing Escherichia coli. J Clin Microbiol 1997; 35:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Importance of culture confirmation of shiga toxin-producing Escherichia coli infection as illustrated by outbreaks of gastroenteritis--New York and North Carolina, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:1042.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.rki.de/EN/Home/homepage__node.html (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/media/releases/2011/s0601_ecoligermany.html?s_cid=2011_s0601_ecoligermany (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/48\">",
"      Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004; 350:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/49\">",
"      Nelson JM, Griffin PM, Jones TF, et al. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites. Clin Infect Dis 2011; 52:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/50\">",
"      Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/51\">",
"      Proulx F, Turgeon JP, Delage G, et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992; 121:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/52\">",
"      Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992; 20:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/53\">",
"      Zhang X, McDaniel AD, Wolf LE, et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/54\">",
"      Pavia AT, Nichols CR, Green DP, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990; 116:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/55\">",
"      Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/56\">",
"      Smith KE, Wilker PR, Reiter PL, et al. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 2012; 31:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/57\">",
"      Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012; 55:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/58\">",
"      Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/59\">",
"      Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14232/abstract/60\">",
"      Watanabe M, Matsuoka K, Kita E, et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 2004; 189:360.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2714 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14232=[""].join("\n");
var outline_f13_57_14232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4451659\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7485212\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemolytic-uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5636939\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6412743\">",
"      E. coli O157:H7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6412751\">",
"      E. coli O104:H4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20808880\">",
"      Role of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20808907\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4451659\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2714|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/709\" title=\"picture 1\">",
"      Kidney glomerulus EHEC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/63/31730?source=related_link\">",
"      Patient information: E. coli (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14233="Oligohydramnios";
var content_f13_57_14233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oligohydramnios",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Ron Beloosesky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Michael G Ross, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14233/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/57/14233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligohydramnios refers to amniotic fluid volume that is less than expected for gestational age. It is typically diagnosed by ultrasound examination and may be described qualitatively (eg, normal, reduced) or quantitatively (eg, amniotic fluid index [AFI] &lt;5). Methods of amniotic fluid volume assessment are reviewed separately.",
"   </p>",
"   <p>",
"    In this topic, we use the term oligohydramnios to describe pregnancies with AFI &lt;5 cm and",
"    <span class=\"nowrap\">",
"     borderline/low",
"    </span>",
"    normal amniotic fluid volume to describe pregnancies with AFI 5 to 8 cm. Alternatively, some clinicians prefer the single vertical pocket (SVP) with severe oligohydramnios defined as SVP less than 1 cm and mild oligohydramnios defined as SVP 1 to 2 cm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An adequate volume of amniotic fluid is critical to allow normal fetal movement and growth, and to cushion the fetus and umbilical cord. Oligohydramnios may inhibit these processes and can lead to fetal deformation, umbilical cord compression, and death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported rates of oligohydramnios are influenced by variations in diagnostic criteria, the population studied (low or high risk, screening or indicated ultrasound examination), the threshold used, and the gestational age at the time of the ultrasound examination (preterm, term, or postterm).",
"   </p>",
"   <p>",
"    A study of 3050 uncomplicated pregnancies with singleton non-anomalous fetuses between 40 and 41.6 weeks of gestation noted oligohydramnios (defined as AFI less than 5) in 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence is high in laboring women, largely due to rupture of fetal membranes during or just before labor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of amniotic fluid is ultimately determined by the volume of fluid flowing into and out of the amniotic sac. Fetal urination, lung fluid, and swallowing all make important contributions to fluid movement in late gestation, with minimal contributions from other sources. Fetal disorders that affect any of these processes will affect the amniotic fluid volume. As an example, growth restricted fetuses may redistribute blood flow away from their kidneys, which decreases fetal urine production, resulting in oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homeostatic mechanisms, such as intramembranous absorption (transfer of amniotic fluid across the amnion into the fetal circulation), also exist and work to maintain amniotic fluid volume. These mechanisms appear to be more successful in limiting excess fluid volume than in preventing reduced fluid volume. As an example, only half of fetuses with esophageal atresia, and two-thirds of fetuses with duodenal or proximal jejunal atresia develop polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/6\">",
"     6",
"    </a>",
"    ], whereas renal agenesis invariably results in oligohydramnios.",
"   </p>",
"   <p>",
"    The physiology of normal amniotic fluid production and volume regulation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=see_link\">",
"     \"Physiology of amniotic fluid volume regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions commonly associated with oligohydramnios are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79447 \" href=\"UTD.htm?26/35/27195\">",
"     table 1",
"    </a>",
"    ). The most likely etiologies of oligohydramnios vary according to severity and the trimester in which they are diagnosed. The majority of women with oligohydramnios or",
"    <span class=\"nowrap\">",
"     borderline/low",
"    </span>",
"    normal amniotic fluid volume have no identifiable cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1597700183\">",
"    <span class=\"h2\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of first trimester oligohydramnios is often unclear. Reduced amniotic fluid prior to 10 weeks of gestation is rare because gestational sac fluid is primarily derived from the fetal surface of the placenta, transamniotic flow from the maternal compartment, and secretions from the surface of the body of the embryo.",
"   </p>",
"   <p>",
"    Criteria suggested for determining reduced amniotic fluid at this gestational age have included a difference between mean gestational sac size (MGSS) and crown-rump length of less than 5 mm or a mean gestational sac",
"    <span class=\"nowrap\">",
"     diameter/crown-rump",
"    </span>",
"    length ratio outside the normal range for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. This finding has been associated with poor outcome in selected populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the prognostic value of these findings, when applied to large unselected populations, has not been adequately studied [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1597700190\">",
"    <span class=\"h2\">",
"     Second trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the beginning of the second trimester, fetal urine begins to enter the amniotic sac and the fetus begins to swallow amniotic fluid. Therefore, disorders related to the fetal",
"    <span class=\"nowrap\">",
"     renal/urinary",
"    </span>",
"    system begin to play a prominent role in the etiology of oligohydramnios (",
"    <a class=\"graphic graphic_table graphicRef78227 \" href=\"UTD.htm?14/48/15115\">",
"     table 2",
"    </a>",
"    ). Maternal and placental factors, as well as rupture of the fetal membranes, are also common causes of oligohydramnios in the second trimester.",
"   </p>",
"   <p>",
"    The etiologies and relative frequencies of midtrimester oligohydramnios were illustrated in a series of 128 fetuses first noted to have oligohydramnios at 13 to 24 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/12\">",
"     12",
"    </a>",
"    ]. The following etiologies were observed: fetal anomaly (51 percent), preterm premature rupture of membranes (PPROM) (34 percent), placental abruption (7 percent), fetal growth restriction (FGR) (5 percent), and unknown (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/12\">",
"     12",
"    </a>",
"    ]. Six of the 65 anomalous fetuses were aneuploid. The pregnancy outcome was generally poor due to fetal or neonatal death or pregnancy termination (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Prognosis and management'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    An elevated maternal serum alpha fetoprotein (MSAFP) concentration has also been linked to second trimester oligohydramnios, with or without an anomalous fetus. This combination (elevated MSAFP, decreased amniotic fluid volume) carries an extremely poor prognosis: fetal growth restriction, fetal death, preterm delivery, neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. In one review of these cases, only 8 of 57 (14 percent) children survived past the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/17\">",
"     17",
"    </a>",
"    ]. Oligohydramnios associated with an elevated MSAFP level may be caused by fetal membrane or placental damage, with leakage of amniotic fluid or fetal blood into the maternal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second trimester oligohydramnios related to amniocentesis appears to have a better prognosis. The membranes often \"reseal\" with reaccumulation of amniotic fluid and normal pregnancy outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnostic amniocentesis\", section on 'Leakage of amniotic fluid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a few reports of the occurrence and outcome of oligohydramnios after chorionic villus sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=see_link\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1597700197\">",
"    <span class=\"h2\">",
"     Third trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligohydramnios first diagnosed in the third trimester is often associated with PPROM or with uteroplacental insufficiency due to conditions such as preeclampsia or other maternal vascular diseases. Oligohydramnios frequently accompanies fetal growth restriction related to uteroplacental insufficiency. Fetal anomalies and abruptio placentae also play a role at this gestational age. Amniotic fluid volume normally decreases postterm and oligohydramnios can develop in these pregnancies. In addition, many cases of third trimester oligohydramnios are idiopathic. (See individual topic reviews on these subjects).",
"   </p>",
"   <p>",
"    There may also be an association between pregnancy during the summer season and oligohydramnios, likely related to suboptimal maternal hydration in hot weather [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/21\">",
"     21",
"    </a>",
"    ]. Mechanisms of isolated oligohydramnios also may include alterations in the expression of water pores (aquaporin 1, aquaporin 3) in fetal membranes and placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligohydramnios may be first suspected because the uterine size is less than expected for gestational age. Clinical diagnosis is based on the finding of decreased amniotic fluid on ultrasound examination. Methods for assessment of amniotic fluid volume are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are both objective and subjective ultrasound criteria for oligohydramnios. Although use of an objective criterion is generally preferable, subjective suspicion of amniotic fluid volume by experienced examiners has similar sensitivity for diagnosing reduced amniotic fluid volume confirmed by the dye-dilution method, the gold standard for quantifying volume [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/23\">",
"     23",
"    </a>",
"    ]. There are no large studies in women with oligohydramnios comparing the various sonographic methods of amniotic fluid volume assessment against the dye dilution method, and the latter is not useful clinically because it is invasive and time-consuming. Small series have found that objective sonographic measurements often grossly under- or over-estimated oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. In the only study comparing sonographic and magnetic resonance imaging assessment of amniotic fluid volume, both modalities had similar, and relatively poor, efficacy for the detection of oligohydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use the amniotic fluid index (AFI) for diagnosing oligohydramnios. The AFI provides a means of quantifying normal and abnormal fluid volumes and comparing assessments of amniotic fluid volumes across gestation. As the 5th percentile for AFI averages approximately 7 cm throughout gestation, an AFI less than 5 cm is greater than two standard deviations below the mean value [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/30\">",
"     30",
"    </a>",
"    ]. Most studies that found significant morbidity associated with oligohydramnios used an AFI less than 5 cm as the cutoff, rather than the percentile for gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/31\">",
"     31",
"    </a>",
"    ]. Since the AFI remains relatively stable between 22 to 39 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], we feel that using the AFI cutoff of 5 cm rather than using the 5th percentile is more clinically relevant for the diagnosis of oligohydramnios, and represents a volume that may require further assessment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION OF PREGNANCIES WITH OLIGOHYDRAMNIOS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough maternal history and targeted physical examination is performed to look for maternal conditions that may be associated with oligohydramnios (",
"      <a class=\"graphic graphic_table graphicRef79447 \" href=\"UTD.htm?26/35/27195\">",
"       table 1",
"      </a>",
"      ). The effect of maternal medications (eg, prostaglandin synthase inhibitors) may be limited to oligohydramnios, whereas maternal medical disorders often cause a combination of fetal growth restriction and oligohydramnios.",
"     </li>",
"     <li>",
"      A comprehensive sonographic evaluation with fetal biometry is performed, as well as a search for fetal anomalies (",
"      <a class=\"graphic graphic_table graphicRef78227 \" href=\"UTD.htm?14/48/15115\">",
"       table 2",
"      </a>",
"      ), markers suggestive of aneuploidy (eg, increased nuchal translucency), fetal growth restriction, or placental abnormalities (eg, abruption) that may account for decreased amniotic fluid volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"       \"Sonographic findings associated with fetal aneuploidy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"       \"Diagnosis of fetal growth restriction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"       \"Placental abruption: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If PROM is suspected but the diagnosis is uncertain after noninvasive assessments (eg, examination for vaginal pooling, nitrazine and fern tests, Amnisure), indigo-carmine dye can be injected into the amniotic fluid. Fetal membrane rupture is confirmed if dye is observed on a tampon placed in the vagina at the time of the procedure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H4#H4\">",
"       \"Preterm premature rupture of membranes\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there are fetal anomalies, amniocentesis may reveal an abnormal karyotype. Trisomy 13 and triploidy are the most common chromosomal abnormalities associated with early oligohydramnios. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H7#H7\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Fetuses with congenital anomalies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MSAFP, if elevated, also has prognostic significance and can be helpful in counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     METHODS OF INCREASING AMNIOTIC FLUID VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no treatment of oligohydramnios that has been proven to be effective long-term. However, short-term improvement of amniotic fluid volume is possible and may be considered under certain circumstances, such as when a fetal anatomic survey is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Amnioinfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnioinfusion temporarily increases amniotic fluid volume. It has been used in the following settings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=see_link\">",
"     \"Amnioinfusion: Technique\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       To improve detection of fetal anomalies",
"      </strong>",
"      &mdash; During the second trimester, oligohydramnios may limit optimal ultrasound assessment of the fetus. In such cases, transabdominal amnioinfusion of approximately 200 milliliters of saline under ultrasound guidance can provide better visualization of fetal anatomy.",
"      <br/>",
"      <br/>",
"      A review of patients with unexplained midtrimester oligohydramnios who underwent diagnostic antenatal amnioinfusion found that the overall rate of adequate visualization of fetal structures improved from 51 to 77 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/34\">",
"       34",
"      </a>",
"      ]. There was also an improvement (from 12 to 31 percent) in the identification of associated anomalies in fetuses having preinfusion-identified obstructive uropathy. Another study reported that information obtained at amnioinfusion led to a change of etiologic diagnosis in 13 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/35\">",
"       35",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Fetal magnetic resonance imaging, alone or in combination with amnioinfusion, has been used as a complementary imaging method for detecting fetal anomalies in second trimester oligohydramnios.",
"     </li>",
"     <li>",
"      <strong>",
"       To facilitate cephalic version",
"      </strong>",
"      &mdash; Decreased amniotic fluid is considered a relative contraindication to version. One pilot study reported amnioinfusion led to successful external cephalic version in",
"      <span class=\"nowrap\">",
"       6/6",
"      </span>",
"      cases after a failed attempt [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/36\">",
"       36",
"      </a>",
"      ]. In another similar series, version after amnioinfusion was unsuccessful in all seven patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/37\">",
"       37",
"      </a>",
"      ]. Large randomized studies are needed to define the risks and true success rate of this procedure. We feel there are inadequate data to recommend amnioinfusion for this indication.",
"     </li>",
"     <li>",
"      <strong>",
"       To prevent fetal sequelae of oligohydramnios",
"      </strong>",
"      &mdash; Although investigational, serial transabdominal amnioinfusions have been used to improve fetal outcome in pregnancies with idiopathic oligohydramnios [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/38\">",
"       38",
"      </a>",
"      ] or early oligohydramnios due to premature rupture of membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/39\">",
"       39",
"      </a>",
"      ]. A comparative study using an ovine model with complete obstructive uropathy found that serial amnioinfusions through an intraamniotic port-a-cath prevented pulmonary hypoplasia compared to controls who did not undergo serial amnioinfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/40\">",
"       40",
"      </a>",
"      ]. The treated group had lung volumes comparable to the control lambs that underwent a sham operation. Additional studies to confirm these findings are needed prior to clinical utilization of this approach for second trimester oligohydramnios.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Maternal hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral hydration is a means of transiently increasing amniotic fluid volume, and is less invasive than amnioinfusion. Hydration with oral water reduces maternal plasma osmolality and sodium concentration, resulting in an osmotically driven maternal to fetal water flux. Increased placental blood flow volume, fetal urine output, and possibly decreased reabsorption of amniotic fluid via swallowing or intramembranous flow increases the amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This process was illustrated in a prospective study in which 10 women with third-trimester oligohydramnios (AFI less than 5 cm) and 10 controls with normal amniotic fluid volume consumed 2 L of water over two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/42\">",
"     42",
"    </a>",
"    ]. Hydration increased the amniotic fluid volume in women with oligohydramnios (mean change in AFI 3.2 cm, 95% CI 1.1-5.3), but not in those with normal amniotic fluid volume.",
"   </p>",
"   <p>",
"    Three randomized trials of hydration in patients with oligohydramnios have been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, patients with oligohydramnios were randomly assigned to one of four groups: (1) intravenous hypotonic fluid for two hours, (2) intravenous isotonic fluid for two hours, (3) oral water for two hours, or (4) no therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/43\">",
"       43",
"      </a>",
"      ]. Only the groups who received intravenous hypotonic fluid or oral water had an increase in AFI compared with the controls (2.8 and 3.8 cm, respectively, versus 0.5 cm in controls), emphasizing that maternal plasma osmolality reduction rather than maternal plasma volume expansion is etiologic in increasing the amniotic fluid index.",
"     </li>",
"     <li>",
"      The second randomized trial of hydration therapy of women with oligohydramnios compared the AFI effect of maternal intravenous hydration with 0.45 percent normal saline versus placebo therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/44\">",
"       44",
"      </a>",
"      ]. There were no significant differences in AFI between groups, but a slight increase in AFI in both groups.",
"     </li>",
"     <li>",
"      The third randomized trial of pregnancies complicated by third trimester idiopathic&nbsp;oligohydramnios found that long-term hydration (six days) of intravenous isotonic infusion (1500",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      increased the mean AFI from 39.68 &plusmn; 11.11 to 77.70 &plusmn; 15.03 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/45\">",
"       45",
"      </a>",
"      ]. Patients were then randomized to home oral hydration therapy of 1500 or 2500",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      and the higher volume group demonstrated significantly increased amniotic fluid at delivery compared to the lower volume group (112.45 &plusmn; 14.92 versus 86.21 &plusmn; 16.89 mm, respectively P &lt;0.001).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases of oligohydramnios in which delivery is not indicated, we feel that oral hydration may have some benefit, particularly in patients with evidence of maternal dehydration.",
"   </p>",
"   <p>",
"    The combined use of oral water ingestion and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (DDAVP) markedly and transiently increases amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This effect is attributed to both of maternal hydration and antidiuresis, and thus maternal plasma hypoosmolality. Use of DDAVP for this indication should be considered experimental, and used only under approved research protocols.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fetal membrane sealants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tissue sealants (eg, fibrin glue, gelatin sponge, amniopatch) have shown some success in stopping leakage from ruptured membranes in case reports. Neither the safety nor the efficacy of these sealants has been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link&amp;anchor=H24#H24\">",
"     \"Midtrimester preterm premature rupture of membranes\", section on 'Repair of leaks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    prognosis depends on the cause, severity, gestational age at onset, and duration of oligohydramnios. In fetuses with renal anomalies, the type of extra-renal anomalies, if present, also affects prognosis. In all cases, the clinician must consider the complete clinical picture and the risks of intervention prior to clinical management decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     First trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced amniotic fluid at this time is an ominous finding; the pregnancy usually aborts. In one series, 15 of 16 patients (94 percent) with a normal fetal heart rate and small sac noted on first trimester sonogram went on to spontaneously abort compared with only 4 of 52 control patients (8 percent) with normal sac size [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link&amp;anchor=H33#H33\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We counsel these patients regarding the poor prognosis and inform them of the signs of miscarriage. Serial sonographic examinations are helpful for following the natural history of the process (eg, worsening oligohydramnios,",
"    <span class=\"nowrap\">",
"     embryonic/fetal",
"    </span>",
"    demise, or [rarely] resolution).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Second trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second trimester, prognosis and management depend upon the underlying etiology and the severity of oligohydramnios.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Borderline/low",
"       </strong>",
"      </span>",
"      normal amniotic fluid volume",
"      &mdash; Pregnancies with",
"      <span class=\"nowrap\">",
"       borderline/low",
"      </span>",
"      normal amniotic fluid volume generally have a good prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/4,14,48,49\">",
"       4,14,48,49",
"      </a>",
"      ]. Serial sonographic examinations are helpful for following the natural history of the process, which may remain stable, resolve, or progress to development of oligohydramnios",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal growth restriction.",
"     </li>",
"     <li>",
"      <strong>",
"       Oligohydramnios",
"      </strong>",
"      &mdash; In the second trimester, oligohydramnios often ends in fetal or neonatal death. In the large series described above (128 fetuses first noted to have oligohydramnios at 13 to 24 weeks of gestation), survival occurred in",
"      <span class=\"nowrap\">",
"       35/43",
"      </span>",
"      (81 percent) fetuses with PPROM,",
"      <span class=\"nowrap\">",
"       2/9",
"      </span>",
"      (22 percent) fetuses with abruption,",
"      <span class=\"nowrap\">",
"       1/5",
"      </span>",
"      (20 percent) idiopathic cases,",
"      <span class=\"nowrap\">",
"       1/65",
"      </span>",
"      (1.5 percent) fetuses with congenital anomalies, and",
"      <span class=\"nowrap\">",
"       0/6",
"      </span>",
"      fetuses with fetal growth restriction [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/12\">",
"       12",
"      </a>",
"      ]. Many of these women chose pregnancy termination because of the poor prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preterm delivery, either spontaneous or indicated by maternal or fetal complications, occurs in more than 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/4,13-15,35,50,51\">",
"     4,13-15,35,50,51",
"    </a>",
"    ]. Infants may have anatomical and functional abnormalities, such as skeletal deformations, contractures, and pulmonary hypoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link&amp;anchor=H19#H19\">",
"     \"Midtrimester preterm premature rupture of membranes\", section on 'Pulmonary hypoplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link&amp;anchor=H20#H20\">",
"     \"Midtrimester preterm premature rupture of membranes\", section on 'Musculoskeletal development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We initially perform a fetal anatomic survey to look for fetal malformation, which may influence future management. We administer oral maternal hydration or perform amnioinfusion in pregnancies in which the fetus cannot be visualized adequately. If rupture of membranes is uncertain, amnioinfusion with instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    dye facilitates both diagnosis of PPROM and visualization of fetal anomalies. Serial sonographic examinations are obtained to monitor amniotic fluid volume, fetal growth, and fetal well-being. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific pregnancy complications associated with oligohydramnios are managed as appropriate for the condition. (See individual topic reviews on specific chromosomal and congenital anomalies, midtrimester PPROM, maternal medical disorders, preeclampsia, abruptio placenta, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Third trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/2,52\">",
"     2,52",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/53\">",
"     53",
"    </a>",
"    ], studies have shown an inverse relationship between amniotic fluid volume in the third trimester and the incidence of adverse pregnancy outcome. Small sample size likely affected the results of negative studies. Adverse outcomes are related to umbilical cord compression, uteroplacental insufficiency, and meconium aspiration. In particular, uteroplacental insufficiency and cord compression are associated with fetal heart rate abnormalities that result in cesarean delivery and low Apgar scores [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/12,54-57\">",
"     12,54-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study on 28,555 pregnancies&nbsp;to estimate pregnancy and neonatal outcomes in women with decreased AFI between 24 and 34 weeks of gestation found that major malformations were more common in pregnancies with oligohydramnios (AFI &lt;5 cm) and borderline AFI (5 to 8 cm) than in those with normal fluid: major malformations were present in 25, 10, and 2 percent of fetuses, respectively (P&lt;.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/49\">",
"     49",
"    </a>",
"    ]. Among nonanomalous fetuses, complications that occurred more often in pregnancies with oligohydramnios and borderline AFI than in those with normal fluid included preterm birth: 62, 37, and 8 percent, respectively; cesarean delivery for nonreassuring fetal status: 9, 9, and 4 percent, respectively; and birth weight below the third percentile: 37, 21, and 4 percent, respectively.",
"   </p>",
"   <p>",
"    The duration of oligohydramnios is also a prognostic factor. Patients who present with idiopathic oligohydramnios at an earlier gestational age are at risk for adverse perinatal outcomes compared with those presenting later in gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/12,58\">",
"     12,58",
"    </a>",
"    ]. As an example, in one series of 122 cases of oligohydramnios initially diagnosed in the third trimester and 128 cases initially diagnosed in the second trimester, perinatal survival was 85 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the potential high risk of adverse outcome, these pregnancies should undergo assessment of the acute and chronic fetal condition at each prenatal visit and fetal heart rate monitoring during labor (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Labor'",
"    </a>",
"    below). We perform a nonstress test (NST) and AFI (or biophysical profile) once or twice weekly until delivery, depending upon the maternal and fetal condition. Combined use of the NST and AFI is associated with a low rate of unexpected fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doppler velocimetry may have a role in identifying patients with idiopathic oligohydramnios who are at higher risk of adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/62\">",
"     62",
"    </a>",
"    ]. In one retrospective series of 76 patients with oligohydramnios unrelated to PROM or congenital anomalies, the 46 patients with normal",
"    <span class=\"nowrap\">",
"     systolic/diastolic",
"    </span>",
"    ratios demonstrated markedly reduced perinatal morbidity compared with the 30 patients with abnormal",
"    <span class=\"nowrap\">",
"     systolic/diastolic",
"    </span>",
"    ratios (11 versus 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/62\">",
"     62",
"    </a>",
"    ]. These findings, and observations from other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/63\">",
"     63",
"    </a>",
"    ], suggest that avoiding intervention in pregnancies with oligohydramnios and normal Doppler velocimetry may decrease iatrogenic morbidity related to prematurity. Although the role of Doppler velocimetry in managing fetal growth restriction is well established, its use in other circumstances remains to be validated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Timing of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for delivery in women with oligohydramnios attributable to a specific condition (eg, preeclampsia, premature rupture of membranes, fetal growth restriction, congenital anomaly, postterm pregnancy, etc) are discussed separately in topic reviews on these disorders.",
"   </p>",
"   <p>",
"    Timing of delivery in pregnancies complicated by idiopathic oligohydramnios is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/64\">",
"     64",
"    </a>",
"    ]. Only one small, randomized trial has evaluated outcomes with intervention versus expectant management. In this trial, 54 pregnancies beyond 40 weeks of gestation with isolated oligohydramnios were randomly assigned to either induction of labor or expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/65\">",
"     65",
"    </a>",
"    ]. No differences were found for any important maternal or neonatal outcome.",
"   </p>",
"   <p>",
"    Observational studies have reported conflicting results. In one retrospective series, the corrected perinatal mortality rate in structurally normal fetuses with oligohydramnios was significantly lower when delivery was initiated upon diagnosis (in gestations of at least 28 weeks) than with conservative management (18 versus 90 per 1000 births) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/66\">",
"     66",
"    </a>",
"    ]; this suggests that intervention is indicated. However, the groups came from different institutions and time periods, so they may not have been comparable.",
"   </p>",
"   <p>",
"    Most studies have reported no increased risk of fetal acidosis and generally good outcomes in pregnancies with isolated oligohydramnios (AFI &lt;5 cm) in the third trimester (ie, appropriately grown nonanomalous fetus, reassuring fetal heart rate pattern, no maternal disease) when compared to controls with normal amniotic fluid volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/57,67-77\">",
"     57,67-77",
"    </a>",
"    ]. Importantly, most studies examining the benefits of AFI assessments instituted scheduled antenatal testing for these patients, suggesting that oligohydramnios may precede fetal compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/69\">",
"     69",
"    </a>",
"    ]. Alternatively, this may be related, in part, to the low sensitivity and specificity of AFI for uteroplacental insufficiency, especially in the absence of other indicators of impaired placental perfusion, such as fetal growth restriction, preeclampsia, fetal abnormalities, postterm pregnancy, or abruption [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/52,78\">",
"     52,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our indications for delivery in patients with idiopathic oligohydramnios include, but are not limited to, nonreassuring fetal testing or reaching 37 to 38 completed weeks of gestation, regardless of the cervical Bishop score. Delivery as early as 36 to",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Although induction increases the risk of cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/68,77\">",
"     68,77",
"    </a>",
"    ], there is insufficient evidence to assure us that perinatal outcome with continued conservative management of oligohydramnios at term is comparable to that with delivery, even in the presence of an appropriately grown, noncompromised fetus and absence of maternal disease.",
"   </p>",
"   <p>",
"    We do not typically confirm pulmonary maturity prior to delivery in well-dated pregnancies beyond 36 weeks. Amniocentesis can be challenging in the presence of oligohydramnios due to the lack of a fetus- or placenta-free site for needle insertion.",
"   </p>",
"   <p>",
"    Alternatively, the patient can be followed with serial nonstress testing and biophysical profiles until term gestation is reached; the risks and benefits of various management plans should be discussed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither AFI nor single deepest pocket performed on admission to the labor unit accurately predicts the risk of peripartum complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14233/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. We recommend obtaining a short electronic fetal heart rate recording upon admission of patients in labor to help determine whether the fetal heart rate should be monitored continuously or whether intermittent monitoring is likely to be sufficient. If the fetal heart rate is not reactive or fetal heart rate decelerations are present, then we recommend continuous electronic fetal heart rate monitoring during labor. We also consider transcervical amnioinfusion for patients with oligohydramnios and variable fetal heart rate decelerations in labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=see_link\">",
"     \"Amnioinfusion: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=see_link\">",
"     \"Amnioinfusion: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oligohydramnios refers to amniotic fluid volume that is less than expected for gestational age. It is typically diagnosed by ultrasound examination and may be described qualitatively or quantitatively (eg, amniotic fluid index [AFI] &lt;5). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conditions commonly associated with oligohydramnios are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef79447 \" href=\"UTD.htm?26/35/27195\">",
"       table 1",
"      </a>",
"      ). The most likely etiologies of oligohydramnios vary according to the trimester in which it is diagnosed. The majority of women with mild oligohydramnios have no identifiable cause. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal history and physical examination and a comprehensive sonographic evaluation are recommended for all pregnancies with oligohydramnios. Use of additional tests (eg, karyotype, instillation of dye) depends upon individual clinical circumstances. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation of pregnancies with oligohydramnios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no effective long-term treatment of oligohydramnios. In idiopathic oligohydramnios, maternal treatment with intravenous isotonic solution, oral hydration, or amnioinfusion can lead to short-term improvement. These procedures may be useful under certain circumstances, such as to facilitate diagnostic ultrasound evaluation when the fetal anatomic survey is suboptimal. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Methods of increasing amniotic fluid volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reduced amniotic fluid in the first trimester appears to be an ominous finding. We counsel these patients regarding the poor prognosis, discuss the signs of miscarriage, and follow the pregnancy with serial ultrasound examinations to determine its course. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'First trimester'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis and management of second trimester oligohydramnios depend upon the underlying etiology and severity of oligohydramnios. Mild idiopathic oligohydramnios has a relatively good prognosis. Severe oligohydramnios diagnosed at this time may induce anatomical and functional fetal abnormalities and often results in fetal or neonatal death.",
"      <br/>",
"      <br/>",
"      We initially perform a fetal structural survey to rule out a fetal malformation since serious abnormalities may influence future management. Serial sonographic examinations to monitor amniotic fluid volume, fetal growth, and fetal well-being are performed until delivery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Second trimester'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some studies have shown an inverse relationship between amniotic fluid volume in the third trimester and the incidence of adverse pregnancy outcome. Adverse outcomes are related to umbilical cord compression, uteroplacental insufficiency, and meconium aspiration. Given the potential high risk of adverse outcome, we perform a nonstress test (NST) and AFI (or biophysical profile) once or twice weekly until delivery. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Third trimester'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with idiopathic oligohydramnios, we suggest delivery at 37 to 38 completed weeks of gestation rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although induction of an unfavorable cervix increases the risk of cesarean delivery, there is insufficient evidence to assure us that perinatal outcome with continued conservative management of oligohydramnios at term is comparable to that with delivery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Timing of delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/1\">",
"      Locatelli A, Zagarella A, Toso L, et al. Serial assessment of amniotic fluid index in uncomplicated term pregnancies: prognostic value of amniotic fluid reduction. J Matern Fetal Neonatal Med 2004; 15:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/2\">",
"      Rutherford SE, Phelan JP, Smith CV, Jacobs N. The four-quadrant assessment of amniotic fluid volume: an adjunct to antepartum fetal heart rate testing. Obstet Gynecol 1987; 70:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/3\">",
"      Sarno AP Jr, Ahn MO, Brar HS, et al. Intrapartum Doppler velocimetry, amniotic fluid volume, and fetal heart rate as predictors of subsequent fetal distress. I. An initial report. Am J Obstet Gynecol 1989; 161:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/4\">",
"      Mercer LJ, Brown LG, Petres RE, Messer RH. A survey of pregnancies complicated by decreased amniotic fluid. Am J Obstet Gynecol 1984; 149:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/5\">",
"      Yoshimura S, Masuzaki H, Gotoh H, Ishimaru T. Fetal redistribution of blood flow and amniotic fluid volume in growth-retarded fetuses. Early Hum Dev 1997; 47:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/6\">",
"      Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol 2005; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/7\">",
"      Bromley B, Harlow BL, Laboda LA, Benacerraf BR. Small sac size in the first trimester: a predictor of poor fetal outcome. Radiology 1991; 178:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/8\">",
"      Tadmor OP, Achiron R, Rabinowiz R, et al. Predicting first-trimester spontaneous abortion. Ratio of mean sac diameter to crown-rump length compared to embryonic heart rate. J Reprod Med 1994; 39:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/9\">",
"      Nazari A, Check JH, Epstein RH, et al. Relationship of small-for-dates sac size to crown-rump length and spontaneous abortion in patients with a known date of ovulation. Obstet Gynecol 1991; 78:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/10\">",
"      Dickey RP, Olar TT, Taylor SN, et al. Relationship of small gestational sac-crown-rump length differences to abortion and abortus karyotypes. Obstet Gynecol 1992; 79:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/11\">",
"      Rowling SE, Coleman BG, Langer JE, et al. First-trimester US parameters of failed pregnancy. Radiology 1997; 203:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/12\">",
"      Shipp TD, Bromley B, Pauker S, et al. Outcome of singleton pregnancies with severe oligohydramnios in the second and third trimesters. Ultrasound Obstet Gynecol 1996; 7:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/13\">",
"      Dyer SN, Burton BK, Nelson LH. Elevated maternal serum alpha-fetoprotein levels and oligohydramnios: poor prognosis for pregnancy outcome. Am J Obstet Gynecol 1987; 157:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/14\">",
"      Richards DS, Seeds JW, Katz VL, et al. Elevated maternal serum alpha-fetoprotein with oligohydramnios: ultrasound evaluation and outcome. Obstet Gynecol 1988; 72:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/15\">",
"      Koontz WL, Seeds JW, Adams NJ, et al. Elevated maternal serum alpha-fetoprotein, second-trimester oligohydramnios, and pregnancy outcome. Obstet Gynecol 1983; 62:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/16\">",
"      Los FJ, Hagenaars AM, Cohen-Overbeek TE, Quartero HW. Maternal serum markers in second-trimester oligohydramnios. Prenat Diagn 1994; 14:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/17\">",
"      Peipert JF, Donnenfeld AE. Oligohydramnios: a review. Obstet Gynecol Surv 1991; 46:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/18\">",
"      Los FJ, Beekhuis JR, Marrink J, et al. Origin of raised maternal serum alpha-fetoprotein levels in second-trimester oligohydramnios. Prenat Diagn 1992; 12:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/19\">",
"      Bronshtein M, Blumenfeld Z. First- and early second-trimester oligohydramnios-a predictor of poor fetal outcome except in iatrogenic oligohydramnios post chorionic villus biopsy. Ultrasound Obstet Gynecol 1991; 1:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/20\">",
"      Cheng EY, Luthy DA, Hickok DE, et al. Transcervical chorionic villus sampling and midtrimester oligohydramnios. Am J Obstet Gynecol 1991; 165:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/21\">",
"      Feldman I, Friger M, Wiznitzer A, et al. Is oligohydramnios more common during the summer season? Arch Gynecol Obstet 2009; 280:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/22\">",
"      Zhu XQ, Jiang SS, Zhu XJ, et al. Expression of aquaporin 1 and aquaporin 3 in fetal membranes and placenta in human term pregnancies with oligohydramnios. Placenta 2009; 30:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/23\">",
"      Magann EF, Perry KG Jr, Chauhan SP, et al. The accuracy of ultrasound evaluation of amniotic fluid volume in singleton pregnancies: the effect of operator experience and ultrasound interpretative technique. J Clin Ultrasound 1997; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/24\">",
"      Chauhan SP, Magann EF, Morrison JC, et al. Ultrasonographic assessment of amniotic fluid does not reflect actual amniotic fluid volume. Am J Obstet Gynecol 1997; 177:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/25\">",
"      Dildy GA 3rd, Lira N, Moise KJ Jr, et al. Amniotic fluid volume assessment: comparison of ultrasonographic estimates versus direct measurements with a dye-dilution technique in human pregnancy. Am J Obstet Gynecol 1992; 167:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/26\">",
"      Magann EF, Nolan TE, Hess LW, et al. Measurement of amniotic fluid volume: accuracy of ultrasonography techniques. Am J Obstet Gynecol 1992; 167:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/27\">",
"      Magann EF, Nevils BG, Chauhan SP, et al. Low amniotic fluid volume is poorly identified in singleton and twin pregnancies using the 2 x 2 cm pocket technique of the biophysical profile. South Med J 1999; 92:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/28\">",
"      Rutherford SE, Smith CV, Phelan JP, et al. Four-quadrant assessment of amniotic fluid volume. Interobserver and intraobserver variation. J Reprod Med 1987; 32:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/29\">",
"      Zaretsky MV, McIntire DD, Reichel TF, Twickler DM. Correlation of measured amnionic fluid volume to sonographic and magnetic resonance predictions. Am J Obstet Gynecol 2004; 191:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/30\">",
"      Moore TR, Cayle JE. The amniotic fluid index in normal human pregnancy. Am J Obstet Gynecol 1990; 162:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/31\">",
"      Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987; 70:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/32\">",
"      Phelan JP, Ahn MO, Smith CV, et al. Amniotic fluid index measurements during pregnancy. J Reprod Med 1987; 32:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/33\">",
"      Crowley P, O'Herlihy C, Boylan P. The value of ultrasound measurement of amniotic fluid volume in the management of prolonged pregnancies. Br J Obstet Gynaecol 1984; 91:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/34\">",
"      Pryde PG, Hallak M, Lauria MR, et al. Severe oligohydramnios with intact membranes: an indication for diagnostic amnioinfusion. Fetal Diagn Ther 2000; 15:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/35\">",
"      Fisk NM, Ronderos-Dumit D, Soliani A, et al. Diagnostic and therapeutic transabdominal amnioinfusion in oligohydramnios. Obstet Gynecol 1991; 78:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/36\">",
"      B&eacute;nifla JL, Goffinet F, Bascou V, et al. [Transabdominal amnio-infusion facilitates external version maneuver after initial failure. Six successful attempts]. J Gynecol Obstet Biol Reprod (Paris) 1995; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/37\">",
"      Adama van Scheltema PN, Feitsma AH, Middeldorp JM, et al. Amnioinfusion to facilitate external cephalic version after initial failure. Obstet Gynecol 2006; 108:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/38\">",
"      Turhan NO, Atacan N. Antepartum prophylactic transabdominal amnioinfusion in preterm pregnancies complicated by oligohydramnios. Int J Gynaecol Obstet 2002; 76:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/39\">",
"      Locatelli A, Ghidini A, Verderio M, et al. Predictors of perinatal survival in a cohort of pregnancies with severe oligohydramnios due to premature rupture of membranes at &lt;26 weeks managed with serial amnioinfusions. Eur J Obstet Gynecol Reprod Biol 2006; 128:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/40\">",
"      Nicksa GA, Yu DC, Kalish BT, et al. Serial amnioinfusions prevent fetal pulmonary hypoplasia in a large animal model of oligohydramnios. J Pediatr Surg 2011; 46:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/41\">",
"      Hofmeyr GJ, G&uuml;lmezoglu AM. Maternal hydration for increasing amniotic fluid volume in oligohydramnios and normal amniotic fluid volume. Cochrane Database Syst Rev 2000; :CD000134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/42\">",
"      Flack NJ, Sepulveda W, Bower S, Fisk NM. Acute maternal hydration in third-trimester oligohydramnios: effects on amniotic fluid volume, uteroplacental perfusion, and fetal blood flow and urine output. Am J Obstet Gynecol 1995; 173:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/43\">",
"      Doi S, Osada H, Seki K, Sekiya S. Effect of maternal hydration on oligohydramnios: a comparison of three volume expansion methods. Obstet Gynecol 1998; 92:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/44\">",
"      Yan-Rosenberg L, Burt B, Bombard AT, et al. A randomized clinical trial comparing the effect of maternal intravenous hydration and placebo on the amniotic fluid index in oligohydramnios. J Matern Fetal Neonatal Med 2007; 20:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/45\">",
"      Patrelli TS, Gizzo S, Cosmi E, et al. Maternal hydration therapy improves the quantity of amniotic fluid and the pregnancy outcome in third-trimester isolated oligohydramnios: a controlled randomized institutional trial. J Ultrasound Med 2012; 31:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/46\">",
"      Ross MG, Nijland MJ, Kullama LK. 1-Deamino-[8-D-arginine] vasopressin-induced maternal plasma hypoosmolality increases ovine amniotic fluid volume. Am J Obstet Gynecol 1996; 174:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/47\">",
"      Nijland MJ, Ross MG, Kullama LK, et al. DDAVP-induced maternal hyposmolality increases ovine fetal urine flow. Am J Physiol 1995; 268:R358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/48\">",
"      Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. Am J Obstet Gynecol 1984; 150:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/49\">",
"      Petrozella LN, Dashe JS, McIntire DD, Leveno KJ. Clinical significance of borderline amniotic fluid index and oligohydramnios in preterm pregnancy. Obstet Gynecol 2011; 117:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/50\">",
"      Moore TR. Superiority of the four-quadrant sum over the single-deepest-pocket technique in ultrasonographic identification of abnormal amniotic fluid volumes. Am J Obstet Gynecol 1990; 163:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/51\">",
"      Mercer LJ, Brown LG. Fetal outcome with oligohydramnios in the second trimester. Obstet Gynecol 1986; 67:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/52\">",
"      Morris JM, Thompson K, Smithey J, et al. The usefulness of ultrasound assessment of amniotic fluid in predicting adverse outcome in prolonged pregnancy: a prospective blinded observational study. BJOG 2003; 110:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/53\">",
"      Magann EF, Doherty DA, Chauhan SP, et al. Dye-determined amniotic fluid volume and intrapartum/neonatal outcome. J Perinatol 2004; 24:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/54\">",
"      Sarno AP Jr, Ahn MO, Phelan JP. Intrapartum amniotic fluid volume at term. Association of ruptured membranes, oligohydramnios and increased fetal risk. J Reprod Med 1990; 35:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/55\">",
"      Chauhan SP, Sanderson M, Hendrix NW, et al. Perinatal outcome and amniotic fluid index in the antepartum and intrapartum periods: A meta-analysis. Am J Obstet Gynecol 1999; 181:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/56\">",
"      Phelan JP. The postdate pregnancy: an overview. Clin Obstet Gynecol 1989; 32:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/57\">",
"      Alchalabi HA, Obeidat BR, Jallad MF, Khader YS. Induction of labor and perinatal outcome: the impact of the amniotic fluid index. Eur J Obstet Gynecol Reprod Biol 2006; 129:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/58\">",
"      Vink J, Hickey K, Ghidini A, et al. Earlier gestational age at ultrasound evaluation predicts adverse neonatal outcomes in the preterm appropriate-for-gestational-age fetus with idiopathic oligohydramnios. Am J Perinatol 2009; 26:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/59\">",
"      Clark SL, Sabey P, Jolley K. Nonstress testing with acoustic stimulation and amniotic fluid volume assessment: 5973 tests without unexpected fetal death. Am J Obstet Gynecol 1989; 160:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/60\">",
"      Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. Am J Obstet Gynecol 1994; 170:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/61\">",
"      Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. Am J Obstet Gynecol 1996; 174:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/62\">",
"      Carroll BC, Bruner JP. Umbilical artery Doppler velocimetry in pregnancies complicated by oligohydramnios. J Reprod Med 2000; 45:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/63\">",
"      Skotnicki MZ, Rybaczuk M, Urban J. [Doppler examination of fetal cerebral circulation in pregnancies complicated with idiopathic oligohydramnios]. Ginekol Pol 2004; 75:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/64\">",
"      Bannerman CG, Chauhan SP. Oligohydramnios at 34-36 weeks: observe or deliver. Am J Obstet Gynecol 2011; 205:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/65\">",
"      Ek S, Andersson A, Johansson A, Kublicas M. Oligohydramnios in uncomplicated pregnancies beyond 40 completed weeks. A prospective, randomised, pilot study on maternal and neonatal outcomes. Fetal Diagn Ther 2005; 20:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/66\">",
"      Bastide A, Manning F, Harman C, et al. Ultrasound evaluation of amniotic fluid: outcome of pregnancies with severe oligohydramnios. Am J Obstet Gynecol 1986; 154:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/67\">",
"      Zhang J, Troendle J, Meikle S, et al. Isolated oligohydramnios is not associated with adverse perinatal outcomes. BJOG 2004; 111:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/68\">",
"      Danon D, Ben-Haroush A, Yogev Y, et al. Prostaglandin E2 induction of labor for isolated oligohydramnios in women with unfavorable cervix at term. Fetal Diagn Ther 2007; 22:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/69\">",
"      Driggers RW, Holcroft CJ, Blakemore KJ, Graham EM. An amniotic fluid index &lt; or =5 cm within 7 days of delivery in the third trimester is not associated with decreasing umbilical arterial pH and base excess. J Perinatol 2004; 24:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/70\">",
"      Sherer DM. A review of amniotic fluid dynamics and the enigma of isolated oligohydramnios. Am J Perinatol 2002; 19:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/71\">",
"      Conway DL, Adkins WB, Schroeder B, Langer O. Isolated oligohydramnios in the term pregnancy: is it a clinical entity? J Matern Fetal Med 1998; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/72\">",
"      Rainford M, Adair R, Scialli AR, et al. Amniotic fluid index in the uncomplicated term pregnancy. Prediction of outcome. J Reprod Med 2001; 46:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/73\">",
"      Magann EF, Kinsella MJ, Chauhan SP, et al. Does an amniotic fluid index of &lt;/=5 cm necessitate delivery in high-risk pregnancies? A case-control study. Am J Obstet Gynecol 1999; 180:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/74\">",
"      Magann EF, Doherty DA, Field K, et al. Biophysical profile with amniotic fluid volume assessments. Obstet Gynecol 2004; 104:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/75\">",
"      Kreiser D, el-Sayed YY, Sorem KA, et al. Decreased amniotic fluid index in low-risk pregnancy. J Reprod Med 2001; 46:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/76\">",
"      Elsandabesee D, Majumdar S, Sinha S. Obstetricians' attitudes towards 'isolated' oligohydramnios at term. J Obstet Gynaecol 2007; 27:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/77\">",
"      Manzanares S, Carrillo MP, Gonz&aacute;lez-Per&aacute;n E, et al. Isolated oligohydramnios in term pregnancy as an indication for induction of labor. J Matern Fetal Neonatal Med 2007; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/78\">",
"      Magann EF, Chauhan SP, Kinsella MJ, et al. Antenatal testing among 1001 patients at high risk: the role of ultrasonographic estimate of amniotic fluid volume. Am J Obstet Gynecol 1999; 180:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/79\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/80\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/81\">",
"      Chauhan SP, Hendrix NW, Morrison JC, et al. Intrapartum oligohydramnios does not predict adverse peripartum outcome among high-risk parturients. Am J Obstet Gynecol 1997; 176:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/82\">",
"      Moses J, Doherty DA, Magann EF, et al. A randomized clinical trial of the intrapartum assessment of amniotic fluid volume: amniotic fluid index versus the single deepest pocket technique. Am J Obstet Gynecol 2004; 190:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14233/abstract/83\">",
"      Johnson JM, Chauhan SP, Ennen CS, et al. A comparison of 3 criteria of oligohydramnios in identifying peripartum complications: a secondary analysis. Am J Obstet Gynecol 2007; 197:207.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6777 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14233=[""].join("\n");
var outline_f13_57_14233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1597700183\">",
"      First trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1597700190\">",
"      Second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1597700197\">",
"      Third trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION OF PREGNANCIES WITH OLIGOHYDRAMNIOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      METHODS OF INCREASING AMNIOTIC FLUID VOLUME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Amnioinfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Maternal hydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fetal membrane sealants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      First trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Third trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Timing of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6777\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6777|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/35/27195\" title=\"table 1\">",
"      Causes of oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/48/15115\" title=\"table 2\">",
"      Anomalies associated with oligohydramnios",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=related_link\">",
"      Amnioinfusion: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=related_link\">",
"      Amnioinfusion: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=related_link\">",
"      Midtrimester preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/888?source=related_link\">",
"      Physiology of amniotic fluid volume regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14234="Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children";
var content_f13_57_14234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Manuela Albisetti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Anthony KC Chan, MBBS, FRCPC, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/57/14234/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/57/14234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism (VTE) is increasingly recognized as a major secondary complication of advanced tertiary care in infants and children. Similar to the situation in adults, episodes of VTE may end fatally or cause serious long-term morbidity, including the post-thrombotic syndrome. The long-term morbidities are particularly important for young patients. Some morbidities, such as leg size differences, can have a negative impact on the child&rsquo;s development into a normal healthy adult. Thus, early and proper diagnosis, as well as optimal prophylactic and treatment strategies for VTE in children, are extremely important to avoid such complications.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of VTE in infants and children will be discussed here. Other aspects of VTE are discussed in separate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis and clinical manifestations of VTE in infants and children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VTE in the newborn. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link\">",
"       \"Management of thrombosis in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebral venous thrombosis in children and adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"       \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"       \"Treatment and prognosis of cerebral venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in adults, contrast angiography is considered the gold standard for the diagnosis of venous thromboembolism (VTE) in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/1\">",
"     1",
"    </a>",
"    ]. The need to inject contrast material through a peripheral vein frequently makes contrast angiography unfeasible in children due to poor venous access. For this reason, ultrasound often is used for the initial imaging study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of the jugular and axillary veins, diagnosis of thrombosis in the upper venous system using ultrasound can yield false negative results due to the position of the clavicles (which hinder the view of the distal subclavian veins) and the thoracic cage (which hinders compression of veins in a central location). Thus, a combination of both venography and ultrasound has been suggested to screen for thrombosis in the upper venous system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Based on studies in adults, Doppler ultrasound is recommended for initial evaluation of thrombosis in the lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in adults suggest that gadolinium-enhanced magnetic resonance (MR) venography is a fast and reliable noninvasive procedure with excellent results regarding detection and determination of the extent of thrombo-occlusive disease in the chest veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In children, MR venography has been successfully used to demonstrate congenital vascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/7\">",
"     7",
"    </a>",
"    ]. These initial findings suggest that MR venography may offer significant advantages for the diagnosis of central venous line-related deep vein thrombosis (DVT) in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTITHROMBOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treating venous thromboembolism (VTE) are to prevent local extension of the thrombus and embolization, aid in resolving the existing thrombus, prevent recurrence of VTE, and minimize long-term complications, such as the post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Post-thrombotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, antithrombotic therapy consists of the administration of anticoagulant agents (eg, unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    [UFH], low molecular weight heparin [LMWH], or vitamin K antagonists [VKA]). Thrombolytic agents (eg, urokinase, recombinant tissue plasminogen activator [r-tPA]) are used only in selected patients with major vessel occlusion causing compromise of organs or limbs. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Thrombolytic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A randomized trial in children with VTE comparing treatment with LMWH versus UFH followed by a VKA was closed prematurely due to slow patient accrual [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/9\">",
"     9",
"    </a>",
"    ]. The study as published was underpowered to detect any significant differences between these two treatment approaches. Despite the lack of definite data, LMWH is preferred over standard anticoagulation therapy with UFH and oral anticoagulants in most circumstances, for the reasons detailed below. (See",
"    <a class=\"local\" href=\"#H22597475\">",
"     'LMW heparin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22597475\">",
"    <span class=\"h2\">",
"     LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low molecular weight heparins (LMWHs) are fragments of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    obtained by several processes to yield a mean molecular weight of approximately 4000 to 5000. Like UFH, the antithrombotic activities of LMWHs are mediated by catalysis of antithrombin. In contrast to UFH, however, LMWHs have high specific activity against activated factor X (FXa) and less activity against thrombin in vitro (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/10\">",
"     10",
"    </a>",
"    ]. Because of this property, monitoring of LMWH therapy is only possible using an anti-factor Xa assay and not by activated partial thromboplastin time (aPTT) values. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LMWHs offer several advantages over UFH and VKA, and are particularly suited to the efficient and safe treatment of children with or at risk for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/11\">",
"     11",
"    </a>",
"    ]. LMWHs have superior bioavailability, a longer half-life, and dose-independent clearance, which results in a more predictable anticoagulant response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/12\">",
"     12",
"    </a>",
"    ]. LMWHs can be administered subcutaneously and require minimal laboratory monitoring and dose adjustment, which is critically important for infants and young children with poor venous access. Subcutaneous catheters that can remain in place for seven days can reduce the number of injections to as few as one per week [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/11\">",
"     11",
"    </a>",
"    ]. By contrast, treatment with VKA requires frequent monitoring and dose adjustment. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Vitamin K antagonists'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3410317\">",
"    <span class=\"h3\">",
"     Dosing and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing guidelines for therapeutic and prophylactic LMWH administration in children have been established for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    , reviparin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64075 \" href=\"UTD.htm?15/19/15677\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Because of individual variation in responsiveness, patients undergoing treatment with LMWH should be monitored periodically by checking anti-factor Xa levels; the therapeutic range is between 0.5 and 1.0",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in samples taken four to six hours after the last subcutaneous injection. A nomogram has been developed for dose titration of LMWH in children. (See",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"     \"Enoxaparin: Pediatric drug information\"",
"    </a>",
"    .) The therapeutic dose of LMWH is age-dependent, with newborns having increased dose requirements per body weight compared with older children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/17\">",
"     17",
"    </a>",
"    ]. There is no need of laboratory monitoring when LMWH is used for prophylaxis. LMWH is relatively contraindicated in children with severe renal insufficiency.",
"    <strong>",
"     &nbsp;",
"    </strong>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3410324\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggest a low risk (0 to 5 percent) of clinically significant bleeding in children treated with LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. If clinically significant bleeding occurs following use of LMWH,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    should be administered intravenously and will neutralize approximately 75 percent of the anti-factor Xa activity and reduce or eliminate bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/20\">",
"     20",
"    </a>",
"    ]. The dose of protamine sulfate required is based upon the amount of the dose of LMWH received in the previous three to four hours; 1 mg protamine sulfate can inactivate 100 units of LMWH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1997 the Food and Drug Administration (FDA) Public Health Advisory drew awareness to the formation of spinal epidural hematomas following prophylactic LMWH in patients with epidural catheters. For children requiring lumbar puncture, at least two scheduled doses of LMWH should be omitted prior to the procedure.",
"   </p>",
"   <p>",
"    Other complications, including HIT and osteoporosis, are relatively rare with LMWH compared with UFH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     Heparin",
"    </a>",
"    is a glycosaminoglycan that catalyzes antithrombin (AT) to inhibit the action of several serine proteases within the coagulation cascade, especially thrombin and activated factor X (factor Xa). Unlike LMWH, UFH shows equivalent activity against thrombin and factor Xa (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dose and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most children, we suggest initiating UFH therapy with a loading dose of 75",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of UFH intravenously over 10 minutes. Boluses should be reduced or withheld for patients with significant bleeding risks (eg, children recovering from a neurosurgical procedure or with other risks for intracranial bleeding). The loading dose is followed by a maintenance dose of UFH, which depends on the age of the patient. Infants generally require higher maintenance doses (28",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour) compared with children over one year of age (20",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour) and adults (18",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The increased requirement for UFH in the young reflects a faster clearance of UFH, due to a larger volume of distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The maintenance dose of UFH should be titrated to a target anti-factor Xa activity range between 0.35 and 0.7",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. Since aPTT does not correlate well with anti-factor Xa, it would be reasonable to obtain both aPTT and anti-factor Xa level to provide guidance to adjust the dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/28\">",
"     28",
"    </a>",
"    ]. Moreover, UFH dosing strategies should take into account the significance of the clot and the potential risk of bleeding in an individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    UFH monitoring strategies extrapolated from adult practice are not appropriate for use in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults, the therapeutic range of UFH for the treatment of VTE is usually measured via the activated partial thromboplastin time (aPTT), using reagents sensitive to the presence of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      . The goal of maintenance heparin therapy is to maintain the aPTT in the range that corresponds roughly to a heparin blood concentration of 0.35 to 0.7",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      by the chromogenic anti-factor Xa heparin assay and 0.2 to 0.4",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      by the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"       protamine sulfate",
"      </a>",
"      titration assay. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical use of coagulation tests\", section on 'Monitoring heparin therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      By contrast, in children and infants, aPTT monitoring is not a reliable marker for therapeutic UFH levels because of age-dependent variations in the mechanism of action of UFH [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/24,25,29,30\">",
"       24,25,29,30",
"      </a>",
"      ]. As an example, in an observational Australian study of 187 children treated with UFH, a significant number of aPTT results were greater than 180 sec or unrecordable (&gt;600 sec) even when",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      levels were in a therapeutic range (anti-factor Xa activity 0.35 to 0.7",
"      <span class=\"nowrap\">",
"       units/mL),",
"      </span>",
"      as determined by two different chromogenic anti-factor Xa heparin assays [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/24\">",
"       24",
"      </a>",
"      ]. These results suggest using only aPTT test results to titrate UFH dosing in children may result in reducing UFH to subtherapeutic levels. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409094\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Bleeding",
"      </strong>",
"      &ndash; Bleeding complications secondary to the use of UFH are usually controlled by termination of the infusion. If the bleeding is life-threatening or immediate reversal is required,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      can be neutralized rapidly by",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"       protamine sulfate",
"      </a>",
"      given intravenously. The dose of protamine sulfate is based upon the amount of heparin received in the previous two hours; 1 mg of protamine sulfate can inactivate 100 units of UFH [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Osteoporosis",
"      </strong>",
"      &ndash; There is some evidence that prolonged use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      contributes to osteoporosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H4#H4\">",
"       \"Drugs that affect bone metabolism\", section on 'Heparin'",
"      </a>",
"      .) Although there are only a few case reports suggesting this possible association in children, the available information in adults suggests that prolonged use of UFH should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       Heparin",
"      </a>",
"      <strong>",
"       -induced thrombocytopenia",
"      </strong>",
"      &ndash; Heparin-induced thrombocytopenia (HIT) is caused by heparin-dependent antiplatelet antibodies. In children, HIT seems to be relatively uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/31-34\">",
"       31-34",
"      </a>",
"      ] but should always be considered when other causes of thrombocytopenia have been excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. If HIT is present, UFH therapy should be discontinued, all other forms of heparin should be stopped (eg, heparin flushes), and another antithrombotic agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/45/4823?source=see_link\">",
"       lepirudin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"       argatroban",
"      </a>",
"      ) employed (",
"      <a class=\"graphic graphic_algorithm graphicRef56493 \" href=\"UTD.htm?31/36/32334\">",
"       algorithm 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/9,37\">",
"       9,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Vitamin K antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant activities of oral vitamin K antagonists (VKA) (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    , phenprocoumon) are mediated by inhibiting the synthesis of biologically active vitamin K-dependent coagulant proteins (factors II, VII, IX, and X) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H6#H6\">",
"     \"Therapeutic use of warfarin\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409065\">",
"    <span class=\"h3\">",
"     Dose and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common method for monitoring oral anticoagulant therapy is via the prothrombin time (PT), which is reported as an international normalized ratio (INR) in order to assure comparability among the various laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical use of coagulation tests\", section on 'Measurement of INR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The therapeutic ranges for oral anticoagulant therapy in children are extrapolated from recommendations for adults, and consist of an INR between 2.0 and 3.0 for treatment of VTE. An initial oral dose of 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 5 mg of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    ) generally is recommended when starting with a normal baseline INR and normal liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. After Fontan procedure, children require significantly lower doses of oral anticoagulants, and an initial dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with mechanical heart valves should be treated according to adult recommendations, in which the target INR varies depending on the valve position and type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    As compared with adults, monitoring oral anticoagulant therapy in children requires more frequent INR measurements and dose adjustments, for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children&rsquo;s diets have a wide range of vitamin K intake. Diets with poor sources of vitamin K, such as breast milk, induce sensitivity to oral anticoagulants (VKA). Diets supplemented with vitamin K, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      or nutrient formula, induce resistance to oral anticoagulants [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most children suffering from serious primary medical problems are taking other medications that can reduce absorption from the intestine or alter the metabolic clearance of oral anticoagulants [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25,39\">",
"       25,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409079\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effect of oral anticoagulants is bleeding. When a reversal of oral anticoagulation therapy is required, vitamin K",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion with fresh frozen plasma (FFP), unactivated prothrombin complex concentrates (factor IX complex), or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/18/44324?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    are effective interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of agent depends upon the clinical situation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of bleeding and no requirement for ongoing oral anticoagulant therapy, vitamin K can be administered at doses of 2 to 5 mg orally.",
"     </li>",
"     <li>",
"      In the absence of bleeding but an ongoing requirement of oral anticoagulants, vitamin K should be administered at lower doses of 0.5 to 2 mg orally, since larger doses can make the patient temporarily resistant to the further action of oral vitamin K antagonists. Successful lowering of high INRs with a single IV dose of 30",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      of vitamin K has been reported, whereas repeated doses were required in children with liver dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the presence of clinically significant but not life-threatening bleeding, vitamin K can be administered at doses of 0.5 to 2 mg intravenously (but not intramuscularly) in combination with infusion of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of fresh frozen plasma (FFP).",
"     </li>",
"     <li>",
"      In the presence of central nervous system bleeding, vitamin K can be administered intravenously at doses of 5 to 10 mg by slow infusion over 10 to 20 minutes in combination with infusion of 50",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      of prothrombin complex concentrate. Alternatively, the IV administration of recombinant factor VIIa may be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other side effects of oral anticoagulants, such as tracheal calcification or hair loss, rarely are seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thrombolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic agents mediate their activity by catalyzing the conversion of endogenous plasminogen to plasmin. The thrombolytic agents commonly used in children are recombinant tissue plasminogen activator (r-tPA) and urokinase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=see_link&amp;anchor=H2#H2\">",
"     \"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis\", section on 'The fibrinolytic system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recombinant tPA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human recombinant tPA (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"     alteplase",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    ) is produced by endothelial cells as a single-chain polypeptide, which is converted to a two-chain molecule. The high affinity of tPA for plasminogen in the presence of fibrin allows efficient activation on the fibrin clot and subsequent fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25,45,46\">",
"     25,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to adults, there are limited data on the efficacy, dose, and safety of thrombolytic agents in children, and indications for thrombolytic therapy remain highly individualized [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25,46,47\">",
"     25,46,47",
"    </a>",
"    ]. In case series, thrombolytic agents have been administered systemically as a continuous infusion with or without an initial bolus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/48-50\">",
"     48-50",
"    </a>",
"    ], through catheter-directed administration [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/50\">",
"     50",
"    </a>",
"    ], or in diluted low-doses instilled into central venous lines (CVL) to restore catheter patency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Systemic or catheter-directed thrombolysis",
"      </strong>",
"      &ndash; Systemic thrombolytic therapy should be reserved for infants and children with major vessel occlusion causing compromise of organs or limbs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"       25",
"      </a>",
"      ]. Thrombolytic therapy is NOT recommended in patients with right-to-left cardiac shunts because of the risk of arterial emboli to the central nervous system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For systemic thrombolysis, recommended doses of recombinant tPA vary between 0.1 and 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour for a duration of six hours [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"       25",
"      </a>",
"      ]. One can re-evaluate the clinical situation and decide to give more than one course of tPA. Some authors suggest that a low-dose infusion of recombinant tPA (0.01 to 0.06",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour for up to 96 hours) may have a decreased incidence of major bleeding and can be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/48,50\">",
"       48,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Catheter-directed thrombolysis refers to a low-dose infusion of recombinant tPA through a catheter with the tip situated within the thrombus. This approach may offer several advantages over systemic thrombolysis, including higher response rate and decreased rate of major bleeding complications [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/46\">",
"       46",
"      </a>",
"      ]. The recommended dose for catheter-directed thrombolysis with recombinant tPA is 0.01",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour for 24 hours. Catheter-directed thrombolysis can be considered especially if the catheter is already close to the thrombus.",
"     </li>",
"     <li>",
"      The efficacy of thrombolytic agents including tPA is reduced in the setting of low plasminogen levels, which are normally seen in neonates. Therefore, supplementary treatment with plasminogen (as fresh frozen plasma [FFP]) is suggested in neonates or in patients with low plasminogen levels (suggested by fibrinogen levels &lt;1",
"      <span class=\"nowrap\">",
"       g/L).",
"      </span>",
"      Endogenous plasminogen also is depleted by thrombolytic agents, an effect known as \"plasminogen steal.\" Therefore, either monitoring the fibrinogen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasminogen concentration or supplementary treatment with plasminogen should be considered when thrombolytic therapy is administered for more than 24 hours. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Blocked CVL",
"      </strong>",
"      &ndash; When a CVL is blocked (but no definite thrombus is identified), tPA may be used to lyse any intraluminal thrombus and restore catheter patency. For this purpose, recommended doses of recombinant tPA, available as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/2/12328?source=see_link\">",
"       alteplase",
"      </a>",
"      , are a solution containing 0.5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      with instillation of 1",
"      <span class=\"nowrap\">",
"       mL/lumen",
"      </span>",
"      in children under 10 kg, and a solution containing 1.0",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      with instillation of a maximum of 2",
"      <span class=\"nowrap\">",
"       mL/lumen",
"      </span>",
"      in children over 10 kg. After a dwell time of two to four hours, an attempt to withdraw samples from the catheter should be performed. If the first attempt is unsuccessful, the CVL may be treated with a second course of recombinant tPA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25,54\">",
"       25,54",
"      </a>",
"      ]. If the CVL remains blocked after two doses of tPA, an imaging study (ultrasound or contrast venography) should be performed to determine if there is a catheter-related thrombosis.",
"      <br/>",
"      <br/>",
"      Recombinant tPA is also available in 2",
"      <span class=\"nowrap\">",
"       mg/vial",
"      </span>",
"      (Cathflo Activase&reg; or Actilyse Cathflo&reg;) for the exclusive indication of restoring catheter patency. Recommended doses in children are 2 mg instillations for children weighing 30 kg or more, and instillations of a volume equal to 110 percent of the estimated internal lumen volume of the dysfunctional CVL (to not exceed 2 mg) for children weighing less than 30 kg. A study in children has shown that this formulation of alteplase is safe and very effective in the restoration of function to occluded CVL in infants and children [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Urokinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urokinase is isolated as a single-chain form (scu-PA) from human urine and fetal kidney cell cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/56\">",
"     56",
"    </a>",
"    ]. In the presence of a thrombus, scu-PA induces activation of plasminogen and clot lysis with production of a two-chain form (tcu-PA) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/57\">",
"     57",
"    </a>",
"    ]. Urokinase, which had been off the market for some time in the United States, is again available; however, treatment of pulmonary embolism is the only FDA-approved indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complication of thrombolytic therapy is bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before thrombolytic therapy is initiated, potential concurrent hemostatic defects such as thrombocytopenia and vitamin K deficiency should be corrected. In patients who are at high risk for bleeding, thrombolytic therapy should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mild hemorrhagic complications secondary to thrombolytic therapy can be treated with local pressure and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/62/2020?source=see_link\">",
"       topical thrombin",
"      </a>",
"      preparations.",
"     </li>",
"     <li>",
"      Treatment of major bleeding from a local site consists of stopping thrombolytic therapy and intravenous administration of FFP or cryoprecipitate along with other blood products if necessary. If concomitant",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      therapy is administered, cessation and reversal of heparin with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/18/18724?source=see_link\">",
"       protamine sulfate",
"      </a>",
"      should be considered. If the bleeding is life-threatening, administration of an antifibrinolytic agent (amicar) should also be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     New anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several new anticoagulants, such as factor Xa inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) and direct thrombin inhibitors (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/13/14551?source=see_link\">",
"     argatroban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ), have been tested and in part approved for use in adults. However, there are limited data on their use in children, and are restricted to small clinical trials. For this reason, the use of these agents in children is not recommended until results of ongoing clinical trials become available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of thrombosis in the newborn\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for antithrombotic therapy in children are extrapolated from adult guidelines. Specific recommendations depend on the cause of venous thromboembolism (VTE), as are outlined below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409167\">",
"    <span class=\"h2\">",
"     Secondary venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis during childhood is almost exclusively secondary and develops in those children with serious underlying conditions and risk factors. Of these risk factors, the most common in tertiary care settings is the presence of a central (indwelling) venous line (CVL). Other risk factors include surgery, trauma, use of oral contraceptives, immobilization, infection, systemic lupus erythematosus, structural venous abnormalities, cancer, and inherited thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409174\">",
"    <span class=\"h3\">",
"     CVL related VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants and children with CVL-related VTE, guidelines recommend initial anticoagulation with either low molecular weight heparins (LMWH) or unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) for 5 to 10 days, followed by three months of either LMWH or vitamin K antagonists (VKA) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. If VKA is used, the treatment should overlap with",
"    <span class=\"nowrap\">",
"     UFH/LMWH",
"    </span>",
"    until the international normalized ratio (INR) is in the therapeutic range (ie, 2.0 to 3.0) on two consecutive days. If clinically feasible, CVL should be removed after three to five days of anticoagulation therapy. If the CVL is required and still functioning, prophylactic doses of LMWH should be given to prevent recurrent VTE following therapeutic anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. In children with ongoing but potentially reversible risk factors (eg, nephrotic syndrome or Kawasaki disease), guidelines suggest extending anticoagulant therapy beyond three months until the risk factor has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Thrombolytic therapy is suggested in infants and children with major vessel occlusion causing compromise of organs or limbs. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Thrombolytic agents'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2949033\">",
"    <span class=\"h3\">",
"     Thromboembolism in children with cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of thromboembolism in children with cancer requires special consideration, because these patients typically are undergoing treatment with drugs that may affect anticoagulation decisions, have CVLs, and often need surgical procedures. The evaluation and management of these patients is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/12/41160?source=see_link\">",
"     \"Thromboembolism in children with cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409259\">",
"    <span class=\"h3\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of VTE in children with systemic lupus erythematosus are treated with initial",
"    <span class=\"nowrap\">",
"     UFH/LMWH,",
"    </span>",
"    and subsequently with either LMWH or VKA. The duration of therapy depends upon the persistent presence of antiphospholipid antibodies (aPL) and, to a lesser extent, the location of the thrombus. The most common approach in children with a first VTE is indefinite anticoagulant therapy as long as aPL are present. In children with recurrent VTE and aPL, life-long anticoagulant therapy is recommended.",
"    <br/>",
"    <br/>",
"    The presence of lupus anticoagulants (LAs) in plasma may interfere with the coagulation tests used to monitor",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    and VKA. If LAs interfere with the (activated partial thromboplastin time) aPTT, either an insensitive aPTT reagent or a heparin assay should be used to monitor heparin therapy. If the LAs interfere with the PT, plasma concentration of prothrombin can be used to monitor oral anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409298\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pulmonary embolism (PE) includes initial administration of LMWH or UFH for 7 to 10 days, then transitioned to long-term anticoagulation with either LMWH or oral anticoagulants. The anticoagulation treatment should be continued for a minimum of three months for PE with a transient risk factor (such as surgery), and six months for unprovoked PE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The oral anticoagulants can be started one or two days after initiation of therapeutic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link&amp;anchor=H27#H27\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'First episode of PE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to use thrombolytic agents (eg, tissue plasminogen activator [tPA] or urokinase) should be individualized and considered in children with extensive and hemodynamically compromising PE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Thrombolytic agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3409919\">",
"    <span class=\"h2\">",
"     Idiopathic VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;VTE is considered idiopathic if there is no identifiable disorder or CVL that predisposes the patient to thrombosis. In contrast to adults, idiopathic thrombosis in children is rare. Treatment for children with idiopathic VTE is similar to that for secondary VTE (see",
"    <a class=\"local\" href=\"#H3409174\">",
"     'CVL related VTE'",
"    </a>",
"    above), except that treatment for 6 to 12 months is suggested. Children with recurrent idiopathic VTE should be treated indefinitely with VKAs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. Children with idiopathic VTE should be screened for inherited thrombophilias (activated protein C [APC] resistance or factor V Leiden genotype; prothrombin G20210A mutation, and deficiency of protein C, S and antithrombin) and for the presence of antiphospholipid antibodies, as outlined in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hereditary thrombotic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. The most frequent causes of an inherited (primary) hypercoagulable state are the factor V Leiden mutation and the prothrombin gene mutation, which together account for 50 to 60 percent of cases. Defects in protein S, protein C, and antithrombin (formerly known as antithrombin III) account for most of the remaining cases, while a rare cause is one of the various dysfibrinogenemias. Screening for and management of inherited thrombophilias are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=see_link\">",
"     \"Screening for inherited thrombophilia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Considerations relevant to specific types of inherited thrombophilias are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22598121\">",
"    <span class=\"h3\">",
"     Heterozygous protein S or C deficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of VTE in children with heterozygous protein S or C deficiency requires initial administration of LMWH or UFH and maintenance therapy with either LMWH or VKA for a total of three to six months. (See",
"      <a class=\"local\" href=\"#H22597475\">",
"       'LMW heparin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Unfractionated heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic anticoagulation therapy can be considered in patients with these deficiencies under conditions that put them at high risk for developing VTE, such as cardiac catheterization in small infants, treatment with L-asparaginase, immobility, major orthopedic surgery, or trauma in teenagers. In low-risk situations, prophylactic anticoagulation therapy may not be beneficial and, therefore, is not recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22598143\">",
"    <span class=\"h3\">",
"     Homozygous protein S or C deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homozygous protein S or C deficiency is a very rare but serious disease that usually manifests in the neonatal period with potentially lethal thrombotic events known as neonatal purpura fulminans. Individuals with homozygous protein S or C deficiency require life-long treatment with anticoagulants. Recurrent thrombotic complications during long-term treatment with oral anticoagulants may be treated with fresh frozen plasma (FFP) in patients with protein S deficiency, or with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"     protein C concentrate",
"    </a>",
"    in patients with protein C deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/62\">",
"     62",
"    </a>",
"    ]. The clinical presentation and management of neonatal purpura fulminans is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of thrombosis in the newborn\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22598166\">",
"    <span class=\"h3\">",
"     Antithrombin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of VTE in a patient with congenital antithrombin (AT) deficiency requires initial administration of LMWH or UFH, followed by VKA or LMWH. In some cases, transfusion with fresh frozen plasma (FFP) or AT concentrates may be necessary in order to provide a substrate for the action of UFH or LMWH (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"UTD.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19520928\">",
"    <span class=\"h1\">",
"     PRIMARY PROPHYLAXIS FOR VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for primary prophylaxis in children without a prior episode of venous thromboembolism (VTE) are not well established, because the evidence base in this age group is limited. In general, the use of physical methods for VTE risk reduction (eg, compression stockings and intermittent pneumatic compression devices, in older children) is encouraged for hospitalized patients with risk factors for VTE, including immobility and critical illness. The use of anticoagulant chemoprophylaxis is limited to selected patients with multiple risk factors for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/3\">",
"     3",
"    </a>",
"    ], because prophylactic treatment carries its own risks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/63\">",
"     63",
"    </a>",
"    ]. The evidence base and specific indications are discussed in detail in a guideline from the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]. When making decisions about thromboprophylaxis, the clinician should also consider additional risk factors for thrombosis in an individual patient, such as mechanical ventilation, systemic infection, hospitalization duration of five days or more, puberty, oral contraceptive use, known thrombophilia, severe obesity, and prolonged immobility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/64\">",
"     64",
"    </a>",
"    ]. A first pediatric specific VTE risk prediction rule has been developed and validated. This rule may assist clinicians to identify high-risk children with a predisposition for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/65\">",
"     65",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Specifically, routine use of antithrombotic therapy is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended for the following groups of patients, unless additional significant risk factors are present (such as a known hereditary thrombotic disorder or history of prior VTE) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with central venous access lines",
"     </li>",
"     <li>",
"      Children with cancer and central venous access devices (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/12/41160?source=see_link&amp;anchor=H18#H18\">",
"       \"Thromboembolism in children with cancer\", section on 'Primary prevention'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, routine use of antithrombotic therapy is suggested for the following groups of patients (at prophylactic doses (",
"    <a class=\"graphic graphic_table graphicRef64075 \" href=\"UTD.htm?15/19/15677\">",
"     table 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children receiving long-term home parenteral nutrition [",
"      <a class=\"abstract\" href=\"UTD.htm?13/57/14234/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Children with some forms of congenital heart disease, postoperatively (eg, bilateral cavopulmonary shunts), or those with primary pulmonary hypertension &nbsp;",
"     </li>",
"     <li>",
"      Children with giant coronary aneurysms following Kawasaki disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H13231780#H13231780\">",
"       \"Cardiovascular sequelae of Kawasaki disease\", section on 'Prevention of coronary thrombosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, antithrombotic therapy is indicated for secondary prevention of some forms of acute arterial ischemic stroke (AIS) in neonates and children, with or without antiplatelet therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=see_link\">",
"     \"Ischemic stroke in children: Secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=see_link&amp;anchor=H386299#H386299\">",
"     \"Stroke in the newborn\", section on 'Arterial ischemic stroke management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These recommendations for prophylactic antithrombotic therapy are distinct from the routine use of low-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    flushes or infusions to maintain CVL patency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H22502891#H22502891\">",
"     \"Management of thrombosis in the newborn\", section on 'Central venous catheters'",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22598112\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism (VTE) is a common complication of indwelling central venous lines (CVL) in children. Less commonly, they are caused by hereditary thrombotic disorders. Treatment recommendations depend on the cause, and are extrapolated from guidelines in adults. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in adults, contrast angiography is considered the gold standard for the diagnosis of VTE in children. The need to inject contrast material through a peripheral vein frequently makes contrast angiography unfeasible in children due to poor venous access. For this reason, ultrasound often is used for the initial imaging study, but there are risks of false-negative results. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For antithrombotic therapy in children, we suggest use of low-molecular weight",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) over unfractionated heparin (UFH) in most circumstances (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is because LMWH has superior bioavailability, a longer half-life, and dose-independent clearance as compared with UFH, which results in a more predictable anticoagulant response. LMWH also has the advantage that it can be administered subcutaneously with minimal laboratory monitoring and dose adjustment. In most circumstances, LMWH also is preferred over vitamin K antagonists (VKA) (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"       warfarin",
"      </a>",
"      ), because the response to VKAs in children tends to be unpredictable and requires frequent monitoring and dose adjustment. Nonetheless, VKA may be preferred by patients requiring long-term therapy, because they are administered orally. (See",
"      <a class=\"local\" href=\"#H22597475\">",
"       'LMW heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When anticoagulation treatment is indicated for acquired VTE in children, treatment should be initiated with LMWH or UFH for 5 to 10 days, followed by LMWH or VKA. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LMWH dosing is based on age and body weight (",
"      <a class=\"graphic graphic_table graphicRef64075 \" href=\"UTD.htm?15/19/15677\">",
"       table 1",
"      </a>",
"      ), and the dose is titrated to achieve anti-Factor Xa activity levels between 0.5 and 1",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"      A nomogram has been developed for dose titration of LMWH in children. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=see_link\">",
"       \"Enoxaparin: Pediatric drug information\"",
"      </a>",
"      .) Activated partial thromboplastin time (aPTT) values are not reliable for monitoring LMWH dosing. (See",
"      <a class=\"local\" href=\"#H22597475\">",
"       'LMW heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      UFH therapy is typically initiated with an initial bolus, followed by a maintenance dose titrated to a target anti-factor Xa activity range between 0.35 and 0.7",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"      The initial bolus should be reduced or withheld for patients with significant bleeding risks. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Unfractionated heparin'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For VTE associated with CVLs, we suggest initial anticoagulation with either low molecular weight heparins (LMWH) or unfractionated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH) for 5 to 10 days, followed by three months of either LMWH or vitamin K antagonists (VKA), rather than observation or shorter courses of treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If clinically feasible, CVL should be removed after three to five days of anticoagulation therapy. (See",
"      <a class=\"local\" href=\"#H3409174\">",
"       'CVL related VTE'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For other causes of secondary VTE, we suggest initial anticoagulation therapy for three months rather than observation or no treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For idiopathic VTE, we suggest anticoagulation therapy for 6 to 12 months rather than a shorter course of treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3409167\">",
"       'Secondary venous thromboembolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3409919\">",
"       'Idiopathic VTE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic thrombolytic therapy should be reserved for infants and children with major vessel occlusion causing compromise of organs or limbs, because this therapy is associated with significant bleeding risks. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bleeding risk'",
"      </a>",
"      above.) When thrombolysis is indicated, we suggest use of recombinant tissue plasminogen activator (tPA) rather than urokinase, because of modest advantages in efficacy and safety (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recombinant tPA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a CVL is blocked (but no definite thrombus is identified), tPA or urokinase may be used to lyse any intraluminal thrombus and restore catheter patency; it is administered as a dwell into the catheter. Lower doses of the thrombolytic agent are used for this purpose as compared with systemic thrombolysis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Recombinant tPA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children presenting with pulmonary embolus should be treated with LMWH or UFH for 7 to 10 days. If the PE is extensive, treatment should be continued with LMWH or oral anticoagulation for three to six months. (See",
"      <a class=\"local\" href=\"#H3409298\">",
"       'Pulmonary embolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with heterozygous protein S or C deficiency, we recommend anticoagulant treatment after an episode of VTE. We do not recommend prophylactic anticoagulation for patients who have not experienced a VTE except in high-risk situations. (See",
"      <a class=\"local\" href=\"#H22598121\">",
"       'Heterozygous protein S or C deficiency'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/1\">",
"      David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the Subcommittee on Perinatal Haemostasis of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/2\">",
"      Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002; 87:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/3\">",
"      Chalmers E, Ganesen V, Liesner R, et al. Guideline on the investigation, management and prevention of venous thrombosis in children. Br J Haematol 2011; 154:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/4\">",
"      Kroencke TJ, Taupitz M, Arnold R, et al. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. Chest 2001; 120:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/5\">",
"      Thornton MJ, Ryan R, Varghese JC, et al. A three-dimensional gadolinium-enhanced MR venography technique for imaging central veins. AJR Am J Roentgenol 1999; 173:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/6\">",
"      Shinde TS, Lee VS, Rofsky NM, et al. Three-dimensional gadolinium-enhanced MR venographic evaluation of patency of central veins in the thorax: initial experience. Radiology 1999; 213:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/7\">",
"      Laor T, Burrows PE, Hoffer FA. Magnetic resonance venography of congenital vascular malformations of the extremities. Pediatr Radiol 1996; 26:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/8\">",
"      Revel-Vilk S, Sharathkumar A, Massicotte P, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. J Thromb Haemost 2004; 2:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/9\">",
"      Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/10\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/11\">",
"      Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/12\">",
"      Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/13\">",
"      Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/14\">",
"      Massicotte P, Julian JA, Marzinotto V, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003; 109:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/15\">",
"      Nohe N, Flemmer A, R&uuml;mler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158 Suppl 3:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/16\">",
"      Revel-Vilk S, Chan AK. Anticoagulation therapy in children. Semin Thromb Hemost 2003; 29:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/17\">",
"      Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/18\">",
"      Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/19\">",
"      Punzalan RC, Hillery CA, Montgomery RR, et al. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/20\">",
"      Van Ryn-McKenna J, Cai L, Ofosu FA, et al. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/21\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/22\">",
"      Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/23\">",
"      Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/24\">",
"      Ignjatovic V, Summerhayes R, Than J, et al. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 2006; 4:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/25\">",
"      Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/26\">",
"      Andrew M, Ofosu F, Schmidt B, et al. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 1988; 52:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/27\">",
"      McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. Pediatr Res 1981; 15:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/28\">",
"      Schechter T, Finkelstein Y, Ali M, et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost 2012; 10:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/29\">",
"      Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/30\">",
"      Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics 2009; 123:e510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/31\">",
"      Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003; 39:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/32\">",
"      Schmugge M, Risch L, Huber AR, et al. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/33\">",
"      Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001; 27:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/34\">",
"      Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 2004; 91:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/35\">",
"      Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf 1997; 17:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/36\">",
"      Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/37\">",
"      Wilhelm MJ, Schmid C, Kececioglu D, et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996; 61:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/38\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/39\">",
"      Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/40\">",
"      Newall F, Barnes C, Savoia H, et al. Warfarin therapy in children who require long-term total parenteral nutrition. Pediatrics 2003; 112:e386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/41\">",
"      Bolton-Maggs P, Brook L. The use of vitamin K for reversal of over-warfarinization in children. Br J Haematol 2002; 118:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/42\">",
"      Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 9:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/43\">",
"      Muleo G, Santoro R, Iannaccaro PG, et al. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. Blood Coagul Fibrinolysis 1999; 10:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/44\">",
"      Taybi H, Capitanio MA. Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology 1990; 176:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/45\">",
"      Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/46\">",
"      Albisetti M. Thrombolytic therapy in children. Thromb Res 2006; 118:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/47\">",
"      Manco-Johnson MJ, Grabowski EF, Hellgreen M, et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 88:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/48\">",
"      Wang M, Hays T, Balasa V, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003; 25:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/49\">",
"      Gupta AA, Leaker M, Andrew M, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/50\">",
"      Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/51\">",
"      Shen V, Li X, Murdock M, et al. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol 2003; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/52\">",
"      Chesler L, Feusner JH. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol 2002; 24:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/53\">",
"      Terrill KR, Lemons RS, Goldsby RE. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer. J Pediatr Hematol Oncol 2003; 25:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/54\">",
"      Choi M, Massicotte MP, Marzinotto V, et al. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 2001; 139:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/55\">",
"      Blaney M, Shen V, Kerner JA, et al. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study). J Vasc Interv Radiol 2006; 17:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/56\">",
"      Stump DC, Thienpont M, Collen D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 1986; 261:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/57\">",
"      Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/58\">",
"      Tuckuviene R, Christensen AL, Helgestad J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr 2011; 159:663.",
"     </a>",
"    </li>",
"    <li>",
"     Andrew M, Monagle P, Brooker LA. Thromboembolic complications during infancy and childhood, B C Dekker Inc, Hamilton, Ontario 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/60\">",
"      Biss TT, Brand&atilde;o LR, Kahr WH, et al. Clinical features and outcome of pulmonary embolism in children. Br J Haematol 2008; 142:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/61\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/62\">",
"      Kroiss S, Albisetti M. Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency. Biologics 2010; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/63\">",
"      Cavo M, Wang W, O'Brien SH. Use of low molecular weight heparin for thromboprophylaxis in a pediatric inpatient population: reasons for use and incidence of bleeding complications. Thromb Res 2010; 125:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/64\">",
"      Branchford BR, Mourani P, Bajaj L, et al. Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica 2012; 97:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/65\">",
"      Sharathkumar AA, Mahajerin A, Heidt L, et al. Risk-prediction tool for identifying hospitalized children with a predisposition for development of venous thromboembolism: Peds-Clot clinical Decision Rule. J Thromb Haemost 2012; 10:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/57/14234/abstract/66\">",
"      Vegting IL, Tabbers MM, Benninga MA, et al. Prophylactic anticoagulation decreases catheter-related thrombosis and occlusion in children with home parenteral nutrition. JPEN J Parenter Enteral Nutr 2012; 36:456.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5916 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14234=[""].join("\n");
var outline_f13_57_14234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22598112\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTITHROMBOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22597475\">",
"      LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3410317\">",
"      - Dosing and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3410324\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dose and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3409094\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Vitamin K antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3409065\">",
"      - Dose and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3409079\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thrombolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recombinant tPA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Urokinase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      New anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3409167\">",
"      Secondary venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3409174\">",
"      - CVL related VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2949033\">",
"      - Thromboembolism in children with cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3409259\">",
"      - Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3409298\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3409919\">",
"      Idiopathic VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hereditary thrombotic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22598121\">",
"      - Heterozygous protein S or C deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22598143\">",
"      - Homozygous protein S or C deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22598166\">",
"      - Antithrombin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19520928\">",
"      PRIMARY PROPHYLAXIS FOR VTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22598112\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5916|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/36/32334\" title=\"algorithm 1\">",
"      Algorithm HIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5916|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/16/36110\" title=\"figure 1\">",
"      Mechanisms of action of heparin LMW heparin and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/19/15677\" title=\"table 1\">",
"      LMW heparin pediatric doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/55/42872?source=related_link\">",
"      Enoxaparin: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27063?source=related_link\">",
"      Ischemic stroke in children: Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14825?source=related_link\">",
"      Screening for inherited thrombophilia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/12/41160?source=related_link\">",
"      Thromboembolism in children with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21450?source=related_link\">",
"      Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_57_14235="Supine hypotensive syndrome";
var content_f13_57_14235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms attributed to supine hypotensive syndrome in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Faintness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dizziness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restlessness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual disturbances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Numbness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresthesias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold, clammy skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pallor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14235=[""].join("\n");
var outline_f13_57_14235=null;
var title_f13_57_14236="Diagnostic criteria for DISH";
var content_f13_57_14236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Published criteria for the diagnosis of diffuse idiopathic skeletal hyperostosis (DISH)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria of Resnick and Niwayama",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. The presence of flowing calcification and ossification along the anterolateral aspect of at least four contiguous vertebral bodies with or without associated localized pointed excrescences at the intervening vertebral body-intervertebral disc junctions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. The presence of relative preservation of intervertebral disc height in the involved vertebral segment and the absence of extensive radiographic changes of \"degenerative\" disc disease, including vacuum phenomena and vertebral body marginal sclerosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. The absence of apophyseal joint bony ankylosis and sacroiliac joint erosion, sclerosis, or intraarticular osseous fusion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria of Utsinger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Continuous ossification along the anterolateral aspect of at least four contiguous vertebral bodies, primarily in the thoracolumbar spine. Ossification begins as a fine ribbon-like wave of bone but commonly develops into a broad, bumpy, buttress-like band of bone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Continuous ossification along the anterolateral aspect of at least two contiguous vertebral bodies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Symmetrical and peripheral enthesopathy involving the posterior heel, superior patella or olecranon, with the entheseal new bone having a well-defined cortical margin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Exclusions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        i) abnormal disc space height in the involved areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ii) apophyseal joint ankylosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Categories of DISH according to the Utsinger criteria are:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Definite = criterion 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Probable = criteria 2 and 3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Resnick D, Niwayama G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology 1976;119:559; and Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985; 11:325.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14236=[""].join("\n");
var outline_f13_57_14236=null;
var title_f13_57_14237="Cold water immersion tx of exertional heat illness";
var content_f13_57_14237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for cold water immersion treatment of exertional heat illness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Contact emergency medical services (EMS) immediately.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess airway, breathing, circulation, and mental status; measure vital signs before immersing the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If appropriate medical staff is present on-site (eg, team physician), equipment for aggressive cooling is readily available (eg, cold water immersion, ice/wet towel rotation, high-flow cold water dousing), and",
"        <strong>",
"         no other emergency medical treatment is needed",
"        </strong>",
"        other than rapid lowering of the body temperature, follow the \"cool-first, transport second\" guideline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        For patients to be treated with ice water immersion, prepare as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Get help.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Move patient to a shaded area.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Half fill a tub or wading pool with water and ice. Ice should cover the surface of the water at all times.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A whirlpool tub filled with ice water may be used if the athlete collapses near an athletic training room.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        During ice water immersion treatment, assess the patient's core body temperature with a rectal thermistor continuously (a thermistor is a flexible thermometer that remains in place throughout the cooling and treatment process).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obtain necessary assistance and cool the patient as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Place the athlete in the ice water immersion tub.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cover as much of the body as possible with ice water. If complete coverage is not possible, cover the torso as much as possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keep the athlete's head and neck above water. An assistant or two can do so by holding the victim under the axillae with a towel or sheet wrapped across the chest and under the arms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Place a towel soaked in ice water over the head and neck while the body is being cooled.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keep water temperature under 15&deg;C (60&deg;F).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vigorously circulate water throughout the cooling process.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor vital signs approximately every 10 minutes and mental status continually during cooling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have several additional assistants immediately nearby in case the athlete becomes combative or must be lifted or rolled because of vomiting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continue cooling until the patient's rectal temperature reaches 39&deg;C (102&deg;F). If the rectal temperature cannot be measured and on-site ice water immersion is indicated, cool for 10 to 15 minutes and then transport to the emergency department. Cooling via ice water immersion occurs at a rate of approximately 1&deg;C for every five minutes (or 1&deg;F every three minutes), if the water is aggressively stirred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the patient from the immersion tub and transfer to the nearest emergency department or hospital after the rectal temperature reaches 39&deg;C (102&deg;F).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If ice water immersion is not feasible given the constraints of the environment, and on-site cooling is appropriate, then cool the patient using the best available means. These may include any of the following three methods:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fill a cooler with ice, water, and 12 towels. Place six icy wet towels all over the patient's body. Leave them in place for two to three minutes, then place those back in cooler and replace them with the six others. Continue this rotation every two to three minutes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Douse the patient continuously with cold water using a shower or hose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If ice is available but no tub, place the patient in a tarp or sheet, cover the patient with a large amount of ice, and then wrap the tarp or sheet around them. Replenish the ice as soon as a moderate degree of melting occurs.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The Korey Stringer Institute (ksi.uconn.edu) and Casa DJ, McDermott BM, Lee EC, et al. Cold-water immersion: The gold standard for exertional heat stroke treatment. Exercise and Sports Science Reviews. 2007; 35:141.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14237=[""].join("\n");
var outline_f13_57_14237=null;
var title_f13_57_14238="Causes of hemoptysis in children";
var content_f13_57_14238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hemoptysis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lung abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Histoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Coccidioidomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Stachybotrys atra",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tracheobronchitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            HIV",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Influenza (eg, H1N1)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vasculitic syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Immune complex mediated",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Henoch-Sch&ouml;nlein purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pauci-immune mediated vasculitic syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Polyarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Other immune mediated diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Idiopathic pulmonary hemosiderosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Goodpasture's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Allergic bronchopulmonary aspergillosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Beh&ccedil;et syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Congenital heart defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Absence of pulmonary artery or veins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eisenmenger syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetralogy of Fallot",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Post Fontan procedure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lung malformations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary sequestration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchogenic cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pulmonary vascular disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arteriovenous malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Telangiectasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Portal vein obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemangioma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neoplasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Papillomatosis carcinoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignant neoplasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bronchial artery aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            History of trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Laceration vocal cords",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tracheotomy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suctioning of airways",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Transbronchial biopsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iatrogenic (eg, perforation of pulmonary artery during placement of a Swan-Ganz catheter)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptogenic hemoptysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic pulmonary hemorrhage of infancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Coagulopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Von Willebrand disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thrombocytopenia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticoagulants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kartagener syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Immunodeficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ehlers-Danlos syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Medications (eg, Amiodarone, propylthiouracil, or penicillamine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inhalation of nitrogen dioxide (eg, in ice arena)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inhalation of pesticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory pseudotumor of the lung",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Catamenial hemoptysis (teenage girls)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retained foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crack cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            M&uuml;nchausen syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Imanaka K, Shimizu S, Matsumoto J, et al. Unilateral absence of pulmonary artery and ventricular septal defect in an infant. Ann Thorac Surg 1998; 66:251.",
"      </li>",
"      <li>",
"       Thompson JW. Evaluation and management of hemoptysis in infants and children. Ann Otol Rhinol Laryngol 1996; 105:516.",
"      </li>",
"      <li>",
"       Chung Y, Ahrens WR, Singh J. Massive hemoptysis in a child due to pulmonary arteriovenous malformation. J Emerg Med 1997; 15:317.",
"      </li>",
"      <li>",
"       Alexiou C, Obuszko Z, Beggs D. Inflammatory pseudotumors of the lung. Ann Thorac Surg 1998; 66:948.",
"      </li>",
"      <li>",
"       Kayser K, Plodziszewska M, Waitr E, et al. Diffuse pulmonary hemosiderosis after exposure to pesticides. A case report. Respiration 1998; 65:214.",
"      </li>",
"      <li>",
"       Haura L, Warachit B, Makkoch J, et al. Hemoptysis in children with pandemic influenza H1N1 2009 infection. Southeast Aisian J Trop Med Public Health 2009; 40:1259.",
"      </li>",
"      <li>",
"       Birchard KR. Transthoracic needle biopsy. Semin Intervent Radiol 2011; 28:87.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14238=[""].join("\n");
var outline_f13_57_14238=null;
var title_f13_57_14239="Arcuate uterus";
var content_f13_57_14239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus bicornuate: arcuate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 228px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADkAZYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorG8TeKdD8L2f2rxBqtpp8PYzSAFvZV6k+wFAGzRXjV58edNu7a4m8IaBq+uQQDMl4yC0tU5wN0smAOcdRWVf+MvilewXMhTwn4csrWUw3109wbt7J8DarqCRk70AwD17UrjPeqK+etS8O+ONRnurXVPjBHbXcbLZCG2thar9tdQ0cQYbdwZTnjJ9u1SS/Di5jtRBqnjbxbLqkjPFawrrShNSkSHedh2nyhkMPmyQFzRqI+gaK+bZPA2vWGpxWWg/FDU7CaRord4LzURcMtwRvkgCgDLrGQwOPmz261r6VafE1ZrO40Tx3HfaNdwGZLnWtMWECQOFWIrxIGbk/h70age90V4Po3xR+IdjLHbeIfBK6ncPbG8aPTN8M8MXmMg3xSA8kqSACTjmun8KfHLwZr15FY3F3caNqMmMW2qRGAk+zfd+nIzRcdj1GimxusiB42VkYZDKcginUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVU1XUrLSbGW81O6htLWJSzyzOFUAfWub+Ifje38JW1rBb2smp6/qD+Vp+lwHElw/ck/woOpY8DFeM6p4QvPGE76x8Q9bkvZIYZL6NLK2+06Vp8UbjzYWZD88xUEY68E84pDL+v/FXxN4+ur3R/hZbNp0cNm97/ad+gje5jHygQBxtG5jgMx/LFO8C/DHRrDxGmraybjxRqUFy/wBuvLy6Vv7M/wBGDGOdCxWT5mPK5xkHtXUajbWstrbaZFbTW+iapNDa29hcQm4gurGKDeUhVcGAsMf6w53LT4NU3rbXmqxRJPbyz3ge5njtBoavDiGO8jWTLgj5ckHtwOtPYQ26mm/sqzawsLfXpH0wm3cMLXRZke4XapUkqJNuCOOccdabaanex3G+C4udWS1kmeygF9FDLqkm8pcJJG6Llbf+FvRQcnirsZi1K9ezuLaz1XMiQX9reTNDaw3MMIkjNnE6ncrMRkg8cHnFRvd6lLdyXmpW8sfn29ves0UkWpLFllintbeMAOEYAFnGRyT2xQBNDq/9mJbf2rrNzcafpVwEmvNQ05WXUpJv+PdoZUyPkJClgPrVWWB7KxbTGsLSCNrfZf6IG8mzmkmcvNLFcMod2RRJuVfXtTNSvYtMUpoV9pS3trfHQ9FtrUTPaW7MIyY7qNDgOpVsHgDI6c1l3ENpayS2ujyXmnzQXk0WnyPoct3LbXagyXMsbyE5jkU7R0HPFAzWt501i1uZbHU4LmwiiytvodgftSRTgJbTpI/zCVI92SM8Dp2rRSxb+1j9uTRxcXmqRpGL+8e6N1BbJlZY04WOcYJOBxjJzWDc+JolsPtd1rKNFYSfaxJfxS2kmnzzR/6JBJBEv7xPmbdk8fhUkF1FpdpqFn/aGk2c0kq6WYH0aUW51WUbpZQc7ijq2OoHv6gGnp5iEWmWjweYltdxLLazXqyrp0zmSRLgTPgzE70AQEgZAxwaz9V0FdVha517TbPUJnije5S50Yy3l6ltvWRdqsURm3qY9pB+Y8HtOr2B0WaOwtYZdHt/JstLS1KzRQtG+GuzbyAbPKlPJ3HhRV+z0iRdRNvLa3lyF1G1lupEj+wiS6SPc94rB/3qN8imMcDaRg80COB0bwVrnhbxHIPh34qj07TpNi2ek6pcfaUuZQrPLE6AZhKAqMDJx1NegfDb4pWnii6/sbW7KbQfFKKXfTrpWXzF/vxFgNyn06/hzUVvdY0IPZjTjLfWl3eTWXh4hpbqUuFM0E+QNwB5J5yevFch8SB4Xhiup/E2oaLDc2skgF1bOyauphiQw7HLAGZS2Wz8rAjAoA97or598GftB6Xa2suleJHvNW1K0YRx32mW3mreoRkNtB+V+cMOmQcGukh+I/jfXxI3hL4c3yW6g4uNanFoG9MIRk/nQB69RXjkemfGLUw0+seKvD3huDvFZ2gnKj13Sd/xrE1Hw34VV3Hjv4v39/Mww0X9rRWkeOv+rQ/1pBoe3ajrelabG0mo6nZWqKMlp51QD8zXK3/xd8AWMzxXHizS969RHL5n6rmvLIY/2edId/Mn02+lJyXmee8J/H5hWpZ/E34O6WiQaPo6Ov8AALXRG5z2GUFOzD5HVf8AC+fhyULJ4h3gEj5bOc/+yUW3x5+HE5I/4SNYiBn97azJ/NKzIPjF4NRGS08N+ICq4yItEYAE9qbN8W/BwBafwn4gCnALPoRx7UW8w1Oms/jF8PbvPleLdLXAz+9kMX/oQFb+neNPDGpsq6f4i0i5ZuixXkbE/gDXk178U/hVOwj1Lw1cKSORPoXIx26Zqomsfs/+IAUuLbRLSVuCJ7N7Rh/wLao/Wi3n/X3h8j6CRldQyMGU9CDkGlryOH4XjT7MXvws8X6joysN0UBnF7YyenyPux9QT9Kt6T8QNb0HVrbRviZpCWEl1KsFrrFjl7Gd24CsTzGxOeDx/OkB6jRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKbLIkMbSSuqRqMszHAA9SaAHUV5nrHxh0VbuTT/AAlaX/ivVUba0GlRF44z/ty42gceprMdfi14rMjmbSvBGmOMBCovLxR3JP3AfyxQB65NLHBGZJpEjjHVnYAD8TXN6v8AEDwjo526n4l0i3fpsa7Qt+QOa8S8TaB8N9Ocn4m/ETUfEl8Au62a8JGRzgQw5K/iaTQdX8B20iHwF8JNW1liCUun0/8Adn/tpLnilqx+h6BffH3wBbyiO31O5v3LbcWlnK/4g4AI+lQS/HfQWleKx0DxZeSLnAh0tvm/M5/Sq9n4h+KF8hTRfh1o+iIq/u5NRvlIA9NsYBBpyaf8btQTdPrXhLSiONsFs8uf++gaLeYtR5+NNzI2y2+HPjeWTGQp04r+pqT/AIWp4nb/AFfwr8TnJGNzIvFVYvBnxfkcG4+JVjGO/laWh/oKsr8M/GkqzG8+K2tGSTH+otI4lX6DJx+GKNBg/wAQ/iFMD9h+FV6DuwpudSij/OiHxV8W57gKPh9pcEbJkGXVlOD7kD9MfjSR/B/VSCbr4meMpJezJcqg9uMGuc8f/DnV/CfgTW9asfiL4vkubG3a4RJLrKMV7EAZ/HNGgfMxofCvxQj8TXHifXPC2maxrP2mOeGWDVPIeFIz8sEY6CPk5HVs8k1u6fc/EXSzZzD4W6YhtpJ5IF0zU1hEXm/eJQkq7e579AKybDRPG9xJCfDvxYu5StybSaHUoArrIIRIEjDk+axyOmODntV3/hIfjB4d07z7m40bxBqEFtBc3Wj/AGN1uo1lbaADGArEEHJBOME9KegtSpqnjjWbKMWms+AvE8Q1MwW+r38sLTtdW6Rskm1Yiqxuc8FcdSac/wAUfBQE73d5GriXadJm0025vIAqxxxXMkobc0fzMDkA4Fdr4K+M1nqOvP4c8X6bJ4d8QxzfZ9kkgkt5ZcA7ElHG45GAfXgmvTNR0rT9TVV1GwtLtV6C4hWQD8xRYLnkVpq+j6tcwSPqem61DpWoxT2ur3kcc4MM7EPBAkJ3Ky/Ku5hx3GBSPZ2WnJDZ6LpmiaXfrbTabBaWGobdQilWbzmiSbBVVMZMhBGcnHeuk8QfBfwXq92t7b6c+j6kmTHeaTIbWRGPcbflz9RXG674Y+IXgmyv59M12+8T6TP/AKxUiRdSteMebE5BDtgbTnkjoPRDNyLUhrF5b3+m+INXudMvr6S9sE0PT/KBFuhEsNw7L829hgbsEnGD6RTu+l+G7qXUPEmvrfNpEt3JaaxN5EcMc7hQZJI0JR0OVG05HpWP4e8R2nj62v59PtfE0sl5brNd2UGpxwmwuLcnZCq/KUaYrkn7pz25x1sckkd1NaO2o6FBeXcU92dXQXUNzLcxkC2gZmIUo+3IA25GOhpiI4tRjGp28aaxY3cOk6pb2SR/bXgJjkhAHns+Rcy/xKFxk471C8rDRrM6dPq0dnseC21N7phPYxygl57qOYqMKy4XIJx0xT3luP7Kln1e6u4rNNOkeXUNUtIIhYXNsxVLoWxG4lj8wIJGEXHUVyGm+GNR+LN1d6mLptK8J3scNtd3KWoiu9eEIx5vOfLiJ+6B27egBn+LfGttcQvYt4cuPFWu3lvLaCxljSWayQBAhkMPBjlkQSEFgR9MVu2cHxP1i9W9sPC+jaFLK6zmfWLx7preQReWTDEpxFkZ456816v4N8H6D4M0z7B4b06GytycuVyXkPqzHlj9TW/QB49bfC3xdeWyx678SdUijcfvLXSLaO1iUd1QjoMe3vXM6jonwd8F6xJDeW1x4o8SlsPbsz6jdFsfxL90H64NbnxN8ZXXiLXLnwZ4WvLmzjti/wDa19b4E0m2MubS1B+9Oyg9OmKzvA3gbw9olgLS10a7ur28hhtdT/tktZCW2nkab5uqyzRhcEL6c4oAa3xI8RWtzZ6V4S+H2naTJdXg06Bb26jRo5Chk+eGL5lAUbjk9Mdc10jeDPiZrU7S678QIdKiK4+zaJZAAf8AA3O7+dYt9eGfxx8Mbl30+4lvNQu5ZbzRov8AQbg+S6JmQkkyKqgYz03ele6UAeUf8KL8NXciyeINS8Ra6wO5l1DUnZWP+6u0V0WmfCrwLpgxaeFdKBzndJAJD+bZNdrRQBm2eg6RZJss9KsIF6Yit0UfoK0EjSNQqIqqOgAxinUUAFFFFABWdqOh6VqUbx6hptldI4wwmgV8j8RWjRQB5ff/AAvbQZm1P4X350DUAd72DlpLC7/2XjJ+T/eTGK09C1HTvif4P1PSfEWmfZruJjZ6rpkxy1vKMEFT6HhlYe3pXe15p4jjPhz4yeHdZhULaeIIX0e9xxmZAZIHPqfldPoaANH4QapeXPh640bWZC+s6BctptyzH5pVTBilP+/GVOe5zXdV51cZ0P45Wsi/8e/iXTGicek9qdwP4xyMP+AivRaACiiigAooooAKKKKACiiigAooooAKKKr6jeQadp9ze3biO2tommlc/wAKqCSfyFAHPePvG2m+DLCGS8WW6v7qQQ2Wn2wDT3Uh6Kq+nqegrhrzwTf+LbV9b+LervZaYg80aDa3PlWtsgOf38gwZW9TwPSr3wi0Ztdurn4ja9EX1XWMnT45Rn7DZZPlovoWHzEjrn65j1uwi+J/j6bSbzMvhHw3Iv2uA5C3t8RkIfVI1IJHctigDL8P+IdV1uz/ALK+C/h+w0rw3CxjGt38RSFyOCYYh80h4+8341fh+DH9qzNc+O/FuveIJpOXgWc2tt7gRoen4ivWbeCK2gjgtokhhjAVI41CqoHQADoKkoA5jw74A8J+HFA0bw/p1qwGPMEIZz/wI5P6104AAAHAoooAKKKKACiiigArhPjsjP8AB7xaEbaRYSHPsOSPyFd3XMfE+3W6+G/iiBxlX0y4BGM/8s2oA4DS7u9h07T7aXWdJ1q/0OJZHk1q2+zM93PGGtVjlB2ghW2nGScjvWrcwahZRvBptl4iSK0H2OMWGoxzRyyXOWll/eEtmBiQNxGOMDHTn/CV1qOr+FNDd7iBtUvrW3s5CLqG7tNLlRN9vOYHIPmuCvyg5zipdQtrGaNYoF0ewm1TVlv9Htr6yuLV2vYSTcyT7SOWCkqeBgrwaAJtW0q58W6dcaBrMHiI2To+nLNcadFvS6t/mGoCQEH94AFXA5PpWr8E/FGo3ltceGvEwvhrWmxrNDNfQmGa8tGJEcrISSrDBVge4HrWQ66Pp2t2EhhkENvd3l79sk8QgiCznjCm7C55jLHaq/wkZzzVG3im0Hxd8P8AWr2U28iI+hXdtc3q3U4imZzbzPKPvKzIuMgdepoA92ooooA8u+MXwstPF1r/AGtoscNl4rtGWWC6AKifac+XLtxkHHB6j6VzfhHxTfa9Yz6vZWGqC7M8c11ZpexEXd4sfly2sUczZi8v/WdiduQele615N8QPgdoPi7xIuvQX+o6LqbHdNJYOFErYxvII4bHGR170AczH4Xs/HfxFGixma68N+GrZLXU724md7m9mLtILV5M4eNThmwOoAz0r3yCGO3hjhgjSOGNQiIgwqgcAAdhWF4F8I6V4J8PRaPoUTJbIxkd5G3PK56u57k4H5CugoAK5T4p+LI/BPgPVtcbaZreLbbo38czcIPzI/AGurryj4tSy6n428K6Pb2pv009LjX7i03rGJTCoWBSzcAGRj19KAMbwLY3Wg+E7WyvoraO51Iy3SyTyGT+2ria2LufMUZtgDxkg8CujxtfS5Lw2MdklzYrardAXsCM0DIVtWT5gdxxvkyDz2NSvGY7W5nuW1y1tbi+tb6UxzJfR3XnqEe3VQGIgUkBsADuDisS0sXsrK5GjWGnWc8dognm8MXSNPLNbTc2iRyDG0IfmJIILEGgDn0UXniT4SPYy2t9ax3t0PtmnL9ltyyrLuUWvYjAy/1HOa+g68aCTXPx78P2Vy+o3D6bY32qCa4WMIsdwY0SJQnZMFcnkn1617LQAUUUUAFFFFABRRRQAUUUUAFedfHSN08JadqUWBJpesWN4GP8OJlQn34c16LXnvx1k3+A/wCzYiv2vVL+zsrZW/idp0P6KrH8KAG/Fnbp+qeCNeMmz7BrKQPx1juEaFv1Za9ErifjPpFxrPw11iCyjMt5AqXkCDqzwusoUfXZj8a6bQNVttc0Sw1SxdZLW8hSeNlOeGGaANCiiigAooooAKKKKACiiigAooooAK88+OTS3PhC10KB9j6/qNvpbODgrG75kx/wBWH416HXnPxXbZ4m+HDNgx/2+FKHoSbeUA/hQB3jmDS9MYooS2tYeFHAVFXp+Qrh/gLCR8MdMv5SWu9VeXUrlz1eSWRmJ/LA/Cu+uIUngkhlAaORSjA9wRg1538B7lrbwc/hi9ymq+HJ30+5RhjKhi0cg/2WQgg+xoA9IooooAKKKKACiiigAooooAKhvLdLu0ntpRmOaNo2HsRg/wA6mooA+ZfhXpd2uh3OlLPBc3UF62niOLSoJE0e5t2cRXk+WBbKAYJHr6V3EEby6Zq1+Y9Qs28Q30KW0MFo9vcSXMaEN5z/ADqIpDHjdjaEauf8T2tnonxV1nTL+O6S21jGsWVvbTrANWm8sQyWUhPD5J3AEjlj610Pky6XfCJHg0qS6sWiNvaPcM9lpsMX8AXdGLlHOM45A4oAhljmt3C2cV28du0BlsbKO0lt2/5ZyaVG7bThWBdgewPesT4n6Prl94H8XLp5tNRls5ftEuqXFoEeW2jPnRw2zRE7miYFSWA6niugujcXKWD2qm4vbgodLtjDHMYC2TFqtzGQkitnKv2HpmoITZfZr640p9PubW3tnv7a5ewkttPtpQzRXrNIhyzt+8baRxgYz1oA9X8NanHrXh3TNTgcPFeW0c6sO+5Qf61pV5Z+zfq8V/8ADWDT0mE0uj3EtgzAEbkViY2G4A4KMuM16nQAUUUUAFFFFABXhlqBq/xm8R6rfRadcQW1wnh1TeXRiSGJ4NxRU6StI742n0Ne06pfQ6Zpl5f3Tbbe1heeRvRVUsT+Qrwv4WTanf8AhJWi1KeG71O481g2hNO9pezO0wneR8B18vCg9B8vPSgDpNMsWM2lRwyRW895ZNo732h6dJG9vLbyFsB3BWOEBSoDA5J4PNPvLW388tq2iWVhBeRoGjvGiit7b7TI0dykVxGMvNINpI4B+Xmm6gStydUnk1DTILp/tMkeq6ubcfaUJihgMPzBYpcsTg9hxkUyzt7SyuYNMik0PSMw2mnxxrdG7hivUfzWgS2bAVtrEh855B7UDK3wjtlm+KXjOSNLFLTQ7e20OzFoXYCJS77WZ+S4+UHtkcV7LXmXwMlbUrTxZr3lFYdW124mt3IwZIUCxKcdvuGvTaBBRRRQAUUUUAFFFFABRRRQAV5fDd23jD4pNfvLG/h7wtm1ikkIEcmpuQG2k9Si4X/ec4pPiF44nuLu88M+EbhIr6Ef8TXWJOLfR4sZZmY8GXGdq9jya8k14alf+EtHbwejWXgDR9WtEt5JlP2jWJ2uFDT5/ubmyCcZJ9uAD6R8ZrqUnhXVF0C6W21YQMbaQqGHmAZCkH1xj8a+XfDPxK1/wZc2et6X4V1qHwXqLl5dPf8AfW0LM+Ga3kA+Ql937tuMnH03NX1Qa7L8VI9IvZo/FGi6wutWaJllZLVRHlR0PAYEe460ngnxlqWg3ElxpdpFYXMsY1HUfDE8mIbuNl3m606UkjJX5jHkjPTpQwR9PwyebEkgDKHUNhhgjPrT6zvDus2PiHQ7LVtJnE9jdxiWJxxkH1HYg5BHqK0aACiiigAooooAKKKKACiiigAry34u6laxeLfA1rdXIghs7ufWrpzyI4LeFsswHPVwB+NemXlzDZ2k91cuI4IUaSR26KoGST+Ar5Y1Hx5OdO8S+JxpzX/iDxPZzJptoxyNO0mIFTLJ/dDHLY/iIFIZ9S6de22pafbX1jMs9pcxrNDKnR0YZBH1Brxq4u9R8RC08deB/scfiu1kms7/AEc3QxfW0Urr5bekgxuViOM46Vyela94yn8K+APCngWW0XWrHSI9avVllK+ZCpAigP8AvhgSOO3IFYGm+FPDnjnx9Za7LFf6PF4jWaEvaXOyTT9WiJMsfoQ6gsPWmI+jPAnj3RfGcEq6fK9vqdvxd6bcjZcWzdCrKffuOK6yvDdM+DGv23j3QNb1Dxm+o2ukOWjeS1CXcif883lB+de2WzwSMc17lQAUUUUAFFFFABRRRQAUUUUAeP8A7SmlXv8AwjOmeKNGuJLXUfD92J/tEaK7Rwv8kjBW4OAQfwNQ6NqB1rUY5tBuVn0RfECuG01jYOdse+eWcOMXCMxUnb2PXtXsF5bQ3lpNa3UayQTIY5EYZDKRgg/hXzLYG/8ADGtax4Y8TT6FPZ+HLV4fD/8AaVtI0soucpEdyZPl4Jjb0/DNAHWSLNcWs0Mtuk1/9hmuZrG51HF/Mj3m62WO9XCrCWU4XOegwetb9ut7L4zj8661C/ubPUHEguJ/skOnx3FuCsSqBsu8Y47g1TutOs7eaw0yW2ay0eG4sNOigiC6hZO6MZZI/L+9CQ3ymV+gANQ2k9w9laPPYzXK2Xn6uYFP9oebM8jLB9lu3YIHXrsGeuKBmb8MtTfR/ikkb6xLqen+LbJpkuZ7f7O0t7bMY5P3f8OVGfQ4r3mvnb4jRyW1jY6n9qsLzxHoEtqtlqt3cr9snuWdnazliiXCEoSoB4PrXtXgXxTY+MvC9lremEiG4X542+9FIOGRvcHIoEb9FFFABRRRQB5X+0RdXVx4Mh8NaTF5+qa/OtskQkEf7lP3krFjwqhVwSePmqGSHazQG4uLmCwu77MmsXjWKWwFuNiIFCiaABsbucDJzkVzWrSf8J/8UtRmlFnN4ctLe40G0iureVo7u42eZKd6fcRXRAWyMgYHJro0ujPaWV5PKdRhkSC5kki0s39isUqeQ0Fo3DKC2GYnPy5zwaAK+k21haJY6ay6G8cMmlwiOzsJNRfyXDuqySv/AAF9zJKM7RyeoqDW/E02jeDtT1ae58QrPHZ38qST6XHbq0xlEUJbjIkUkBDn5lyTmr8D6vJ5S7fEUltZxPZXK2SRabbrPbFXV4kf5isufLGG24Fcj4itJfFXjnwZ4ahW/mgM7axqJutU86a1USB3tp4VO0AP5arknHIHegD2H4W+HpPC3w+0PR523XFvbjzm9ZGJZ/8Ax5jXU0VxXj3xnc+C7iK+v9Jmm8MLFuvNQhYM1q+SF/dj5mBJUZ4AznJ6AA7WiuE8G/E/QfFNppbWTzG8vsf6NHC8hjyCSWYLjC8bjnClgDyRXd0AFFFFABRRRQAUUUUAePaP8CdKt9QkbWta1PWNIF1JeRaXOQsHmO24tKB/rWz3at34pNb/AGzwVoreXDazaqtzIv3VENrE8xGPQFE/KvRK8i+L/gfxX4p8XaVNoF5Z2+lyWE2nXsk3MkEcrL5jxjH3mRdoPbn1zRYDlNI0S8h+Hfh34gWdq91qtvqF1rF1BEuXurO5kbzUA7nyyrAdPl96n+Flh4P8dp4l8K+SmueFtLuIrnS3uEZXtVmQl4VJwwCMCB+XavedNsoNO0+1srRAlvbRLDGo/hVQAB+Qp1vaW9vJK9vbxRPKd0jIgUufUkdTQBU8PaLp3h3RrbStFtUtbC2UrFCmSFBJJ68nJJP41o0UUAFFFFABRRRQAUUUUAFFFFAGV4r0SHxJ4a1PRrmWWGG+t3t3kiOGUMMZFeA+N/hdafDT4K+II9F+3atqd+8EF1chP3rW/mrmNQM7Vx9evPHT6TooA+VLOzv/AAdc6R8WfEFrLpUt7qL209iVO2zsGhMcKbOvBRfzHFN+Hfwa1LVvD3gfxXousG0uZbxdT1KGZ3Eb4kJR41APz7SV5wCG/P6g1rSdP1vTpbDV7OC9spcb4Z0Dq2DkcGrNtBFa28UFtGkUEShEjQYVVAwAB2AFAElFFFABRRRQAUUUUAFFFFABRRRQAV5X8ctL1KxtbTxv4WiZte0RHWQKN3m2jqfMBU/e2nDgexr1SmTRpNE8Uqh43UqysMgg8EGgDxHwpdGfTtGu7OTzJr+OO4t5LCIq9xc3MTJJc6haodvlBlGDk9OtWba2tGaCxSDw0bO5uLaG38y8ZrS8S1UvO9tbpxDJG4PGecHJrnLrR7L4T+KX0d4r600HxFdQpp2saeFFzZv5ik2skjf8se49ieuDXbIl9MYpdEje2XUWksbQ6RNBcWunRh3IvQhA+ZicMBn060AY9jJq97YjUbeS51R5Y/Lt77TJLe0i1RpiQbgRsCwkt0AwT12k8CovB13efD/xu0OqQ3cHhjxJcmOGe5mjl23wwolLJwonUBuf4hV2/vrm/mkuYp9ZYq8t5BJd+HhKLOGIeVPAg4bdKPu9cjjvVHUvCcOo+H9V0j/hHtCghvovnjtNSaCaNYxmwBRxhJGO4Hjt3oA9zory34NeKdZKv4P8dpHB4q02BHUiVXF5b9BICDgspBVvcZ7mvUqACvN/jr45j8HeETDbXsFrrWqN9ksnkbAhLcNM3oqA5zjrivQr26hsrOe6upFit4I2lkduiqoySfoBXhehTT+MfGkHivUZrfT49U222gW0sIuWubGMs9wrIfljeQbTknIHGKAL3hrQofDPhjyIGuJLywtYTqc2gai0rvNEwkSFIXGSZldmY8ZyfrWzfXLLJcX2ox6wyaV5ssk80clt5dpcxbikCRA+bJHhF5GVOTnNNt5tYu4I0kj1cziH7S5udFh8+KaZykMisG2boFzuHJ24+lRwW2lJcadrdtqVjBNcypBp+tTM7y3lzK+LiPyGwq7/ACgBjpzgCgBk8NlDbxx6uNLFultul/tW4nuJ7nRoQHErA4xKJGBOR9fSj4Daa2pya/49vY1W58Q3LfZB5AiZbNGIjLAfxN1J74Brm4tN1Px3rEvg+xWbS/CNnGJNd86Uz3JuHkMj2izZIxjZnHAHHtXvlvDFbQRQQRrHDGoREUYCqBgAD0oAg1bULbSdMutQvpDHa20bSyuFLYUDJOBya8fn8d63fx+I7HTPD9zLqN4yPb2moyYighxHFIX25wBlZMA4KyBgRhq9f1nToNX0m8067Mn2e6iaGTy3KNtYYOGHI6145qvgTTvDGoTy+IIJtW8P3kccL324QyaYkQEce9gwLqyMAxAH+r5B3UDO8+FD28vhSKXS7i1uNDLsNMEMRjaC3BwIXB6spBBPU98n5j2dUNAt9PtdDsINGCDTI4EW28tiy+XgbcE5JGMc1foYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDD8beF9N8Y+Gr3RNZi8y1uVxuH3o2H3XU9mB5rwv4fXcmheJl8F69oFva63pOkXNna6jBOYbi/gJZk+zJjaXIBJOc559RX0hXBfF/wADDxn4d32E0ll4i07Nxpl7A5SSKUD7u4c7W6H8D2oAw7eaVbjTxdz6lfzWFna3FnogbOqWzSDyXmuH34kxuYnPHH50L+1ZgLbX7W3vWtrcukWtRCGW7ltJxi7ku4/lVNj5CMM9exNZXg3xTaaz4EU+fdSw2+lx2mpQ2Msk2tw3Rn2Al+Ds6nnpz2rqdQtX0Yas95arp1ndDUriZXX7XYXA8tNtxdkjKE7fuLweaAOT8Z+EGnsp9R8GaLdaLqular9s0m+ts3Q1N5kDPnBJSJjgEk7fzIr174f+JovF3hOw1iOJoJJVKTwPw0Mykq6EdiGBrzsabpF3eWE0+NOF9cWkc75mS1vvLtvMja0COAijH8QAIUgio/gndXGn+OfFOj3WsQaxFqUUOv297bwiKKbzCUkZACRjKqOvUGgC/wDtDazEul6F4Va/hsT4jv0tZ5ZH2hbZSDJz7/Kv/AsUDRW0/S9VsdP8P3NhbXlvdt/YMMqxQzN5gXz/ALWBiFmTBCZAA/GsbXxPrPxm1jVke8ZfCy2FmlnaWSXck6zMZJDtb7g6AuCCApNdFBbeTqU2mwK8Wn3N/fWcunwFb+3laVDIJrpid0I+9+7z/EB3oAivLRk1i0kvLHUIJJZ5DYmbV1m8p4LXEclvCG/eFwTlT3XceuawPFesa5ovhWfUdAXVm8S6nPYWQXW7cqkszxbQ1vGrbY2BYlu2VNX9Iu9NiMOs276dLZx/Z7qW50uBria9cobV2ig5e2RWAG5ewPvVDQdLvL/456ZpupQ6itl4Y0x5oRd6n9rEzNIyRTsB92QqX+982APSgD034a+ELfwR4RtNIgkM84zNdXLZLXE7cvISeeT69gK6miigAprosiFJFVlPUMMg06igBsaLGgSNVVR0CjAFOoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopAQScdutAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUE4GTwKAPnq1tofDvxm8R+HTd3+lf2xfW2uWlxYRczLh/NimcA7Yd4brj9a6SG4tLbSLaSK8v9ChWxdIbmzka90qS4vJSFKk5MrI/OCAAG9Kx/ig0Fz8adBmtLvWCI9MH2pNDw8syfakCpJz/qssxb2rQVIpbZxb6tY3V4kOo6ZnQ5zaXEYiIlW3toOVaVTgFuCMj60AaGm6hHBr0Ri1K3uL57r7NdT6ZbfaG1Rra2PmRTDG23YMeACM8DvWb4ZeYfF3wrbuL53XQryZ5LqCKBkSSaMrAUj4Vo8YI9xV+7mmt4NUhSTULb7bHY3Vt/aVwtlBFdkqBbtLEPMMrEBnBBzkdjVHS7aCD9oHTtSs4vIs9S06/gSBrQwMk0UyGVuQC+9iW3dx0oAh0K1F98QfGduun3FxayeJLRpZIbkW7QGO3D7y2cyLuAHlj1zW013PLpTas/9u3e22ubr7V4fgFul15khiVDCx3PMigMCRj5c57VyOnQWQ+IXiu6u7eC5aHW7qS2UXRS989bKMqLWPhZHOWzuPGFrrRpzS22orpUdzqV7BDp0Ev/ABOGh1PKt5m24c/IhAcHA5cEgnpQA+J0mvQVF9eR6Y3E1ggtr4/ZY1JgmUkNcB3djhBsyeapfBqwNv8AELxvNJc6xdzG300PNqoUTZaJ32sFAwVDKMVoahEdTud8rX98fNkhE0CC21W1DXSj5MBcWwCHLclgM815x4d1/wAf23j74hXPg7w9ouoQm5iuLkLfGVW/dnaI2BGWZRkjseKBn0xRWB4D8TW3jDwpp+t2amNblP3kLEFoZAcOje4IIrfoEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4r8cNWtb/xFZeG9Uvr2z8PWmnza1rTWbFZJYkOyOLcP7z5474H1r2qvmv44gN4i8eeeNynT9FjXBxiM3uWHvyKAOW8K3fh7Qfilo134I0jxho7mwuJbzTZYDJLeqm10RA5OQwDEkHjAxg16dYTS6nGsdzqHiSV47hrM40VLe+t7iVw/2hXHIRIyI2Kg8deorZ+PUA02z8O+K/s00sOgX2+6Ns2yVLaVDG7KR/dLK2PbsM1k6J9j1nRLG0ikud1lYxpFG16n9tWInkO64aYttCtEFbAGcfgKANZLe71aFNSsXghnu4ri7hl+xD7PcToyrC0sEgEzTKiDBGB8v0rmNXvhpnxb+G8hZF/tF5rm5S4eVLlZ7iHYcxuSI4yY1ATPBBFdbaNHPdWNxaXU8xutUmmhYSrqSzW7QlA4cc28TFeSvQgj+KuF1NEv7j4ZeHdGuzcC4vLbVEijRyljDbBjKwMn70q7sceYf4eKBl2Gz1Kb4i/Eaz0qG6ij+0R3TXFrJF59nJ9nRlaFJAcvNgpkYAArq72PUdTGq/abJr63nhsbqKx1JY7WCCYMA6NcR5Z5VKglSMDgdDiub+LUUPhT4gR+INdsEvPCGtLbQajOfMBsZoGJikPl8lTuAxjt9AbaXds3hi6m1G48Mta3WyVrY6bN9iutRnYSwzBzkspXbnA4YHOKBGjFPP8A2lkW091qMBRo3luEstUu447tlbzAQFNsu/I5+b0BNeQ6DpUui+OdW8S2F+qX1l4utNLmisoTaW8sEuFkUxdOrDnP8JPevZ9d1C28NWJvfEb3bWEE1wtyNQtxOs0uFmRklJykKuNqDHXAxwK8+sdPvv8AhVmla7rMbJqfiTxZZalcwuCqxhrhVVQDyBtVevrQB3vwSjOna98RtFVSILXXnuIvQCZFfaB7f1r1WvKfhWWX4rfFWOVh5v220cKDkBDCdp/HH6V6tQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzd8dbdn8S+PYgw+bw7p98cDoIb0k/oDX0jXiPxksmPjaeLarLr3hXUNOUgZZJIh5oP05NAHsZjt9U0nyrmJZrS6h2vG4yHRl5B9iDXiGpfCvxT4aunHgFvD17pSym4s7bWISZrGTaQPLlGSwGTgPkDpivVPhlqo1z4eeHNSACm4sIWYA5w20A/qDXTUAfONv4U+MskNstra+ENHv4bWOx/tSBQtz5KvvKjaCoUnkqFA5Neo/Db4fnwvd3+s65qkuueKNRwLrUZV24QYxHGvRVGP5egrvaKAIL+zttQs5rS+gjuLWZSkkUqhldT1BB615HqHwLtELR+GPFniTQLBm3/Ybe7Lwo2cgqGOR+dex0UAeL+EP2ftD0nU4b/wAQarqfiOe3cSQR3rkRRtnO7Zk7jnnk49Qa6H45OF0Dw+jx+YkniHTlbnBA88HI/LH416PXnvxrZI9D0CWUgRReIdOd8+nnqOPzoAq/DGSNviN8T40Ub11G2LMOhBt1AGfUYPHvXpleXfC6Mx/E34pHHyNqFqR82efIyfp1Feo0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5l8X41tvEvw81UojbNaGnvnvHcxPGw+nT8q9NrG8T+HNP8AEtvYw6osrJZ3kV9F5blCJYzlSSO3tQBz3wYt7qx8Dx6fd6PJpAsbq4tobeRmOYllba4Lc4IPH6cV3Vcf8P8AQbzQL3xRHcpOba71N722mmu/PLq6rkAYGwAggLzXYUAFFFFABRRRQAVxvxehs2+H2qXGoQxTR2QS8QSytEoeNw6ksoJHI9K7KmSxpNE8UqLJG4KsrDIYHqCKAOF8D6Je2Xj3xfrhSD+yNbjsZ7Z45d+91iIc/TlcHvXe0iKqKqooVVGAAMACloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_57_14239=[""].join("\n");
var outline_f13_57_14239=null;
